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ABSTRACT 
 
Nicotine (NIC) addiction remains a prevalent concern in the US. The number of 
users continues to climb while cessation success remains low due to the lack of 
successful available options for quitting. NIC, a well-known weight control substance, is 
appealing for the obese and those who fear becoming obese. Obesity, too, is a major 
concern that remains difficult to treat and overcome. One speculation is that NIC 
cessation-related weight gain provides an increased likelihood of relapse and continued 
use. Ghrelin (GHR), a gut peptide, has been implicated in the endogenous reward system 
of appetitive behaviors, including smoking and unhealthy dietary intake. The effects of 
GHR on feeding and psychostimulant function, accompanied by findings on GHR 
receptor (GHR-R) manipulation, has lead us to investigate possible pharmacological 
dual-treatment approaches for both NIC dependence and smoking cessation-related 
weight gain. The mechanisms of action for NIC and literature supporting GHR’s 
involvement in NIC addiction that favor a dual-treatment hypothesis are investigated 
here.  
Experiment 1 examined the antagonistic effects of the GHR-R antagonist, JMV-
2959, and the agonistic effects of GHR on intracranial self-stimulation (ICSS). 
Experiments 2-3 examined the effects of JMV-2959 on NIC and cocaine intravenous 
self-administration (IVSA). Experiment 4 examined the effects of GHR on cocaine 
IVSA. Experiment 5 examined the effects of JMV-2959 on NIC-cessation related high-
fat (HIFAT) food intake and weight gain. Experiment 6 examined the potential of JMV-
iii		
2959 to induce malaise in a conditioned taste aversion (CTA) task.  
The results for Experiment 1 show that JMV-2959 and GHR alone are incapable 
of mitigating reward-seeking behavior in ICSS. Experiments 2-4’s results show that 
JMV-2959 diminishes the reinforcing effects of NIC and COC IVSA, while GHR alone 
failed to alter COC IVSA. Experiment 5’s results support the notion that JMV-2959 may 
be a useful tool in curbing the general weight gain and NIC cessation-related weight 
gain. Experiment 6’s results confirm that JMV-2959 does not induce malaise.  
Collectively, these experiments provide evidence that GHR is involved in reward-
behavior and that antagonism of GHR-Rs may provide a serious pathway for the dual-
treatment of NIC addiction and weight gain, potentially mitigating drug-seeking for 
other psychostimulants.  
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CHAPTER I 
INTRODUCTION 
 
 Nicotine (NIC) addiction and obesity are two of the leading health 
concerns/issues that contribute to progressive increases in health costs as well as 
increased morbidity rates across the United States (US).  Some 10-25% of 12th graders 
smoke daily and approximately 21% of adults in the US currently smoke cigarettes; a 
number that is rising with every year (CDC, 2004). Due to the health risks associated 
with smoking NIC, the need for successful cessation options must be taken into 
consideration and developed.  Briefly, NIC is a tertiary amine alkaloid that is membrane 
permeable in its uncharged form. It is one of the major ingredients in tobacco and its 
mechanism of action (i.e. receptor activation) is at nicotinic acetylcholine receptors 
(nAChR), which it selectively binds to for activation of neurons (Benowitz 2010).  
Via nAChRs, NIC increases midbrain dopamine (DA) neuron firing, increases 
phasic bursts, while primarily elevating prefrontal cortex (PFC) and nucleus accumbens 
(NAc) DA activity, as well as increasing DA availability in other target regions (DeBiasi 
et al., 2011; Imperato et al., 1986, Grenhoff et al., 1986, Mameli-Engvall et al., 2006, 
Pons et al., 2008, Zhang et al., 2009). Of particular interest is that excitation of ventral 
tegmental area (VTA) DA neurons via NIC binding at nAChRs results in the induction 
of behavioral sensitization via the NAc (Vezina, 2004) (Figure 1; Berton and Nestler, 
2006).  This VTA to NAc connection is better known as the brain’s reward circuit. 
Actively pressing a NIC-infusing lever results in the animal acquiring a long-lasting  
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sensitization of midbrain DA neuron reactivity that will affect continued NIC-related 
behaviors.  These neuromechanistic changes that result in sensitization play a role in the 
initiation, maintenance and escalation of NIC drug use (Changeux, 2010).  
NIC intake for human users occurs through several routes, primarily including, 
but not limited to, tobacco products.  The most concerning form of use is through 
smoking tobacco-containing cigarettes.  Cigarettes consist of shredded tobacco, rolled 
into a paper sleeve, with or without a filter, which is then lit by the user and smoked via 
vapor inhalation through the mouth.  The smoke delivers NIC to the lungs, where it is 
taken up rapidly into the bloodstream and delivered to key areas of action within the 
Figure 1. VTA – NAC Pathway/ Reward 
Circuit.  
(Adapted from Berton and Nestler, 2006) 
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brain.  While the other chemical properties of cigarettes are not the focus of this 
dissertation, it is important to iterate that NIC is not the only component of cigarette 
smoke. 
Tobacco smoke contains around 4000+ chemicals that, when smoked, are 
generally referred to as “tar”, however these chemicals can include, but are not limited 
to: NIC, tar, carbon monoxide, formaldehyde (a preservative), ammonia (a household 
cleaner), hydrogen cyanide, arsenic (used in rat poisons), DDT (a banned insecticide), 
benzene (used to make dyes and synthetic rubber), cadmium (used in batteries), nickel, 
ethyl furoate (causes liver damage), methoprene (a form of insecticide), polonium (a 
cancer-causing radioactive substance), methyl isocyanate (a toxin that killed 2000 people 
in India in 1984) (Agarwal and Bose, 1992), and/or lead (Rabinoff, 2007). While NIC 
addiction does not lead to severe behavioral and cognitive issues, as does cocaine (COC) 
and/or methamphetamine, it is well understood that chronic NIC use via tobacco 
smoking compromises health and leads to early mortality.   
Several health issues that arise from chronic smoking include: smoker’s 
syndrome, increased susceptibility to pneumonia, bronchitis, emphysema, cancers of the 
bladder, esophagus, kidneys, lungs, larynx, mouth, pancreas, and/or stomach, as well as 
an increased risk of heart attack and/or stroke due to cardiovascular disease.  Those 
exposed to second hand smoke, including the unborn, show an increased likelihood of 
heart disease, cancer, and premature death (NIH Cancer Institute, 2014). 
NIC accounts for 6 million annual deaths, with more than 8 million deaths likely 
to occur annually by the year 2030 (Jha et al., 2013).  This translates to about 1 out of 
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every 10 deaths being attributable to a NIC related issue (Degenhardt and Hall, 2001).  
From the perspective of the US, Perkins and Lerman (2014) report that 50 million 
Americans smoke and that smoking accounts for 20% of the mortality in the US – the 
latter translating to about 400,000 preventable deaths per year. 
  Research indicates that most smokers are aware of these health risks and many 
would like to quit. A major issue is that of those who know and desire this, only a few 
will actually make the attempt to quit (Perkins and Lerman, 2014). In fact, few will 
succeed in their quitting attempts. Seventy percent of smokers express a desire to quit, 
however ~80% attempting to quit relapse into smoking again within a month (Dani et 
al., 2007).  Only 5% or fewer will actually succeed in quitting for up to a year.  Most of 
these individuals used an anti-smoking medication to quit, a topic I will also be 
discussing in this dissertation (Perkins and Lerman, 2014). Of those who can quit for 
over a year, only 20% will manage to refrain from smoking for more than 2 years, and 
only 3% will be completely successful in their cessation attempts (Benowitz, 2010). 
These numbers strongly document the severity of the dependence to NIC evident in 
smokers and the difficulty they encounter in cessation compared to other drugs of abuse.  
Thus, one can see why we seek to understand the addictive properties and mechanisms 
of NIC and how we may prevent and/or eliminate addiction, preventing untimely death 
of the user, potential user, and those who encounter second hand smoke.  
A second, and less dangerous, route of NIC intake worth mentioning is NIC use 
through chewing tobacco and snuff/dip.  Through this route, the user takes a chunk of 
cut tobacco and places it in their mouth for chewing or places it in-between their gums 
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and the wall of their mouth.  Here the NIC within the tobacco is absorbed into the saliva 
and then into blood vessels of the walls and gums of the mouth for delivery to the brain. 
Typically, the user periodically spits out the saliva, but some users swallow the saliva, 
which poses a greater health risk for these users beyond the increased likelihood of gum 
disease that comes with this form of tobacco use. 
A few final routes of NIC ingestion discussed here are nicotine replacement 
therapies (NRTs). NRTs may involve NIC-laden chewing gum that functions like 
chewing tobacco without compromising the user’s health if swallowed, transdermal 
patches that are placed on the surface of the skin for delivery through permeation, and 
lastly, electronic cigarettes, or eCigs, in which a chemical mixture containing NIC is 
vaporized and delivered to the lungs.  eCigs are a largely popular substitute for smoking, 
however their comparable safety is still currently under investigation. These NRTs are 
primarily sought out and used by individuals who are attempting to quit 
smoking/dipping.  
 Obesity, briefly mentioned earlier, has also been and remains a major health 
concern in the US as well as other Western European societies.  In spite of efforts to 
identify the underlying metabolic, hormonal, and behavioral underpinnings of this 
disorder, there is evidence that the prevalence of obesity is increasing in American 
children, adults and the elderly (Fakhouri et al., 2012; Flegal et al., 2012; Ogden et al., 
2012, Olshansky et al., 2005).  The National Health and Nutrition Examination Survey 
found that adult (ages starting at 20 and above) obesity prevalence doubled from 1976 to 
1980 and then again from 2007 to 2008, with 34.2% of individuals being overweight, 
 6 
33.8% being obese, and about 5.7% falling into the extremely obese category (CDC, 
2004).  In fact, prevalence of obesity has almost doubled for white, black, and Mexican-
American men from the 1988 to 1994 data to the 2009 to 2010 data, while increasing 
half-fold to one-fold for women of those same categories (Fryar et al., 2012).  Wang et 
al., 2008 found, given this National Health and Nutrition Examination Survey’s data, 
that current linear projection rates would classify more than 51% of Americans as 
obesity by 2030. A recent evaluation by Levi et al., in 2012 concurred with this notion, 
speculating that 44% would be obese by 2030 (Levi, 2013) 
When discussing obesity, it is not uncommon for social stigmatizations to be 
leveled at the obese. Thirty years ago, Vener and Krupka (1985) published findings that 
focused on these social stigmatizations.  They state:  
 We have found that college students are more reluctant to marry the obese than 
to marry cocaine users, ex-mental patients, shop-lifters, the sexually 
promiscuous, communists, the blind, atheists, marijuana users, and the divorced. 
More men than women were disinclined to marry the obese. We also discovered 
that the obese are stigmatized to approximately the same degree as prostitutes and 
embezzlers. The obese find it difficult to obtain jobs that require attractiveness as 
a prime criterion of employment, e.g., flight attendant, receptionist, television 
commentator, hostess, or maître d'hôtel. (Vener and Krupka, 1995) 
 
 These social stigmatizations of the obese have not declined with time and indeed 
likely show higher incidence due to increases in media influences evident on television 
and the Internet.  While all groups are affected by this, the youth and women are often 
targeted and held to a more unrealistic body weight standard than are adult males, 
consequently making obesity a more difficult psychological state for the youth and 
women. 
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 In recent years, considerable effort has sought to determine effective treatments 
for obesity - including drugs that alter metabolism, diminish nutrient absorption or 
suppress appetite (Bray, 2000).  An important component of chronic NIC use, for many 
users, is the potential benefit of weight control afforded by NIC use. Due to the negative 
view of the overweight stated above, many come to discover that smoking assists in 
weight control and this knowledge lead persons to either start NIC usage or to continue 
to use of NIC-containing substances.  
 In knowing that the obese may turn to smoking as a form of weight control, it is 
not surprising that Pomerleau and Kurth (1996) found that 75% of women versus 35% of 
men were unwilling to gain more than 5 pounds if it could be attributed to quitting 
smoking.  The numbers were, of course, higher for willingness to gain 10 pounds or 
more. Sadly, this data is important because cessation of chronic smoking does result in 
weight gain as well as a number of aversive withdrawal symptoms (Benowitz 2010).  
Therefore, the individuals who begin to gain weight after NIC cessation will face an 
increased chance of relapse and may return to chronic NIC use to curb/prevent further 
weight gain and other withdrawal symptoms. 
  Smoking cessation, in fact, can lead to a 3-pound weight gain per 7 days of 
smoking cessation. Pomerlau and Kurth (1996) also found that at any point women who 
quit smoking would fall into 3 weight gain categories.  Approximately 20-30% of 
women will gain less than 5 pounds, most absurdly, ~50% will gain more than 30 
pounds (women who were probably using smoking to control a tendency to overeat), and 
the remainder will gain between 5 and 15 pounds.  Given these facts, the belief that these  
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weight gain issues will likely increase the relapse rate for NIC in these users is not so 
farfetched.  
 While it is unknown how smoking is linked to weight regulation, it is speculated 
to involve a combination of factors including NIC reducing caloric intake, increasing 
activity, increasing metabolic rate, and reducing the formation of fat (lipogenesis) 
(Filozof et al., 2004).  An uncommon practice in NIC studies, or most drug studies in 
which food consumption and weight gain are being measured, is a variation in diet type.  
The US is comprised of a society where multiple fast food restaurants exist within a 
given square mile in larger cities.  Americans are capable of easily accessing and 
enjoying large quantities of proteins, sugars/high-fructose corn syrup, and fats, all of 
which in chronic excess can lead to obesity.  However, in most animal studies with NIC, 
standard chow (CHOW) diet (shown in Figure 2; Envigo, 2015) is primarily and, 
 
Figure 2. Standard Chow 
Macronutritional Information. 
(adapted from Envigo, 2015)	
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typically, solely used for the measure of impact of NIC on food intake and meal size.  
For example, free-feeding rats show a decrease of total CHOW intake and meal size 
when NIC is administered (Bellinger et al., 2003, 2005; Miyata et al., 2001; Grunberg et 
al., 1987; Blaha et al., 1998).  These findings are reliable, but may not be representative 
of the effects on NIC on human food intake.  For example, let us focus on diets of 
smokers versus non-smokers.  To begin with, smokers generally weigh less, ~10 pounds 
on average, than nonsmokers with similar or more amounts of food (Perkins, 1992).  
What does a smoker’s typical diet look like? 
 The study by Dallongeville et al., (1998) which summarize the differences 
between smokers and non-smokers across a multitude of studies for various diet intakes 
are presented in Figure 3.  In this are presented standardized z-scores of energy, fat,  
protein, carbohydrates, alcohol, and fiber intake.  Symbols that are larger than zero 
suggest an intake that is greater in smokers whereas a value that is less than zero 
suggests an intake that is smaller in smokers.  In this study, smokers enjoy a greater 
amount energy intake (+4.9%), as well as a greater amount of fat intake (+3.5%), alcohol 
intake (+77.5%), saturated fat intake (+8.9%) and cholesterol intake (+10.8%) (not 
depicted here) relative to non-smokers.  Smokers can even neglect fiber (-12.4%) and 
several essential vitamins to arrive at a weight that is, on average, about 10 pounds less 
than a non-smoker.  This pattern of dietary intake in smokers is believed to result in an 
increased risk of coronary heart disease and, of course, cancer.  These human data are 
not surprising given that Wellman et al., (2005) noted that NIC had a greater suppressive 
effect on food intake in rats consuming a HIFAT diet than rats consuming a CHOW diet.   
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Moreover, when the NIC treatment was terminated, only rats on the HIFAT diet showed 
a rebound in food intake.  This study remains one of the few animal studies using a 
palatable high-fat diet to assess the impact of NIC on food intake and body weight. 
 While the perceived benefit of weight control due to smoking may seem terribly 
attractive to some, the negative effects of tobacco use (i.e. greatly increased chance of 
cancer and other effects resulting in early mortality) far outweigh this positive effect 
with long term/chronic use and diet/lifestyle doesn’t just end when a chronic smoker 
 
  
Figure 3. Dallongeville et al., 1998’s Typical Smoker’s Diet.  Standardized 
difference (Z-score) of energy, fat (Fat), protein (Pro), carbohydrate (Carb), 
alcohol (Alc) and fiber (Fib) intakes between smokers and nonsmokers. Each 
circle represents the Z-score of an individual study. Positive Z-score 
differences indicate higher and negative differences indicate lower reported 
intakes in smokers than in nonsmokers. (Adapted from Dallongeville et al., 1998)	
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decides to quit.  The mechanism by which NIC controls weight control is currently not 
understood and is a topic of active investigation.  Given what has been discussed so far, 
we can conclude that we should focus on smoking cessation treatment methods that 
target multiple issues, including preventing the rewarding effect of NIC on the brain, 
preventing NIC withdrawal symptoms, and finally preventing weight gain/regain.  Given 
that food reinforcement and drugs of abuse such as NIC exert a shared common action 
on the brain reward circuit, it may be possible to develop multiple modality treatments 
for smoking.  If we can prevent the weight gain/regain pharmacologically, or via diet 
control at a rehabilitation center, while aiding the NIC cessation (e.g. blocking NIC 
induced reward), a rise in smoking cessation success rates may soon follow.  
Current options for aiding cessation in the elimination and prevention of both 
tobacco addiction and weight gain/obesity, both together and independently of one 
another, such as the NRTs previously discussed, remain unsuccessful.  Of interest to us 
are current and widely used cessation options that utilize pharmacological approaches.  
They are intended for those who feel they are unable to quit via weaning or “cold 
turkey,” but have an increased desire to quit for a variety of reasons.  These 
pharmacological approaches include Food & Drug Administration-approved treatments 
such as NRTs, bupropion, and varenicline.  Bupropion is marketed to consumer groups 
as Wellbutrin®, while varenicline is marketed as Chantix®.  
 NRTs are available in several delivery forms: polacrilex (NIC gum), transdermal 
NIC patches, lozenge (oral dissolving tablet), inhaler, and nasal spray (Rose, 2008).  
Paolini and De Biasi (2011) found that, although many smokers will relapse within 6–12 
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months, the use of NRTs can almost double quit rates compared to those given a 
placebo.  This finding, however, is challenged by Harvard School of Public Health 
report in 2012 which showed that the chances of quitting are just as likely for those who 
quit smoking “cold turkey” versus those who seek out NRT approaches (Alpert, 2012).  
Adding to this are Rose et al.’s 2012 findings that the transdermal NIC patch is 
incapable of modifying reward processing, leading to abstinence-induced anhedonia.  
Anhedonia is the inability to feel pleasure and is often linked to depression and is a 
symptom of withdrawal commonly seen in NIC cessation.  This negative symptom is 
therefore positioned to increase the likelihood of drug seeking and consequential relapse.  
Even worse is that some may turn to their feeding habits in an effort to mitigate 
anhedonia and find pleasure once again, thereby promoting weight gain associated with 
smoking cessation (Carton et al., 2000; Hughes, 1996).  
 Varenicline, or Chantix ®, produces significant reduction in negative affect and 
NIC craving in the absence of NIC (Jorenby et al., 2006), but not in restlessness, 
insomnia, or appetite, which the latter is a critical component for smoking cessation.  
Nearly 23% of 12-week varenicline users demonstrated a prolonged effect by abstaining 
successfully for 52 weeks.  The relatively low success rate may be, in part, due to 
varenicline’s side effect profile, as users encounter behavioral changes, feelings of 
depression, thoughts of self-injury, and suicidal behavior (McNeil et al., 2010; Hays and 
Ebbert, 2010, Paolini and De Biasi, 2011).  Other side effects include: difficulty in 
breathing, hyperventilation, shortness of breath, wheezing, headaches, nausea, trouble 
sleeping, etc.  
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 For bupropion, or Wellbutrin ®, it is speculated that the capacity of this drug to 
increase extracellular DA that normalizes NAc DA levels enough to mitigate the 
anhedonic and somatic withdrawal effects that come with NIC cessation (Li et al., 2002).   
However, it is also not side effect free.  Commonly encountered side effects include, but 
are not limited to: anxiety, restlessness, irritability, shaking, dry mouth, irregular 
heartbeats, shortness of breath, hyperventilation, and sleeping difficulty.  Other potential 
side effects during initial bupropion use include: constipation, a decrease in appetite, 
dizziness, an increase sweating, stomach pain, trembling and some weight loss.  
Bupropion is the only option, of the two, that has the ability to decrease appetite to allow 
for continued weight control upon smoking cessation.  
A study published by Luis M. Tuesta et al. in 2011 summarizes the statistical 
success of these two options, however also stating the need to develop more effective 
drugs.  Twenty-three percent of varenicline versus 16% of bupropion users succeed in 
smoking cessation for over a 1-year, while only 9% given a placebo have such success 
rates (Knight et al., 2010).  Drugs like varenicline and bupropion are therefore useful, 
however the incidence of success in smoking cessation is still too low.  Therefore, the 
mechanisms that allow for NIC addiction should be investigated so that we can develop 
better drugs, with more specificity that will allow for greater success.  Overall, it can still 
be argued that, while there is little success, the benefits of both drugs, even when 
considering the withdrawal effects, outweigh the heightened risk of morbidity that 
eventually leads to the early death of half of all chronic and long-term tobacco users. 
While both varenicline and bupropion are statistically effective in promoting 
 14 
quitting, they do not address or target the weight gain among withdrawal symptoms 
generated upon smoking cessation.  As mentioned, bupropion is the only 
pharmacological approach that has some effect in attenuating weight gain, and it does 
this poorly or temporarily with prevalence primarily in individuals that encounter 
depression upon cessation.  Overall, all NRT’s and pharmacological/prescription drug 
approaches fall short of what is important to our lab, fighting the NIC addiction and 
preventing the weight gain/regain associated with smoking cessation, something the 
current approaches have not focused on.   
This has led us to investigate possible common grounds shared by NIC and 
unhealthy food-intake habits.  This common ground would allow us to utilize a dual-
treatment approach for reducing the health issues and morbidity rates of the NIC using 
population that may or may not also be battling obesity.  Findings covered here and 
stated by Tuesta et al. (2011) have led us to investigate possible pharmacological 
approaches with greater specificity resulting in reduced side effects and dual-treatment 
capabilities. 
A speculation was previously made above that the reinforcing properties of drugs 
and food might function via shared circuits.  A study by Di Chiara et al. (2004) supports 
this notion in showing that DA overflow in the VTA to NAc reward circuit can be 
consequent to either psychostimulant or highly palatable foods and may have an additive 
effect when presented together.  This brain region is also understood to be involved in 
the reinforcement of motivated behaviors and therefore places it as a prime target area 
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for this dual-treatment approach.  Of the various manipulations that may alter VTA to 
NAc activity, a change in ghrelin (GHR) signaling is an ideal candidate.   
GHR is secreted peripherally from the stomach and gut in a gradient fashion, 
higher levels from the stomach and lower levels as one travels along the gut.  GHR 
enters the blood stream and then makes its way to the brain where it is known to 
primarily function as an orexigenic peptide (28 amino-acid; see Figure 4; St.Pierre et al., 
2003) (Cummings et al., 2001, Kojima and Kangawa, 2005, Hosoda et al., 2006) by 
binding to the ghrelin receptor (GHR-R), a 7 transmembrane Gq protein coupled 
receptor (Howard et al., 1996; Damian et al., 2012, Uchida et al., 2013).  GHR-R can be 
found on the vagus nerve, putting GHR in a position to alter vagus nerve signaling as 
well as entering through the blood brain barrier to act on brain GHR-Rs.  The brain areas 
in which GHR-Rs are found include the VTA, hippocampus, arcuate nucleus of the 
hypothalamus, NAc, amygdala, and even the Edinger-Westphal nucleus which lies just 
dorsal to the VTA (Kaur and Ryabinin, 2010).  Of specific interest are those GHR-Rs 
located on brain DA neurons found in the reward circuit coursing from the VTA to the 
NAc (Guan et al., 1997, Naleid et al., 2005, Abizaid et al., 2006, Diano et al., 2006).  
Most importantly, and discussed further below, is that GHR has been implicated in the 
modulation of drug and food reinforcement. 
In regards to feeding behavior, GHR increases food intake and shifts preference 
to foods high in fat (Tschop et al., 2000; Shimbara et al., 2004).  Chronic GHR induces  
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overeating and can lead to obesity in high fat fed rats (Tschop et al., 2000).  Antagonism 
of GHR-Rs reduces gastric emptying, reduces food intake, and leads to a loss of body 
weight (Asakawa et al., 2003).  Human GHR levels progressively rise before a meal, 
where they peak and consequently fall following the meal.  Anticipation of a large meal 
results in higher peak levels of GHR prior to the eating (Drazen et al., 2006).  Systemic 
(IP) injections of 6 nMol GHR increase food-seeking behaviors, an effect comparable to 
that induced by 24-hour food deprivation (Davidson et al., 2005).  
Injection of GHR directly into the VTA and/or the NAc can stimulate food 
intake.  Intra-VTA GHR also increases sucrose reward seeking, but injection into the 
Figure 4. Structure of Active Ghrelin. 28 amino acid chain with a n 
octanoyl group at the 3rd serine (Adapted from St.Pierre et al., 2003) 
(Kojima & Kangawa, 2005). 
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NAc does not, suggesting the VTA is a locus for food motivation and reinforcing the 
notion that GHR acts on feeding through multiple pathways (Figlewicz and Sipols, 2010, 
Dickson et al., 2011, Skibicka and Dickson, 2011, Skibicka et al., 2011a).  When the 
VTA is damaged in rats, GHR administration fails to initiate increases in peanut butter 
consumption, however regular chow consumption remains unaffected (Egecioglu et al., 
2010).  ICV infusion at least 1 nMol GHR causes animals to increase their food intake 
(Nakazato et al., 2001) and also results in an increased preference for high fat foods that 
leads to an increase in fat consumption (Shimbara et al., 2004).  Chronic ICV 
administration of GHR leads to weight gain and adiposity (Wren et al., 2001).  Infusion 
of 1 nMol GHR directly into the third ventricle results in increases in food seeking 
behaviors as well (Davidson et al., 2005) and also increases food intake to a larger 
degree in already fat rats as opposed to lean rats.  It is notable that fat rats had 
significantly higher GHR-R mRNA present in the hypothalamus (Brown et al., 2007).  
When infused into the lateral ventricle or fourth ventricle, GHR stimulates food intake 
and increases expression of NPY mRNA (Kinzig et al., 2006, Spinedi et al., 2006), 
which suggests that GHR might exert a secondary action via activation of NPY 
orexigenic circuits.  
Increased GHR levels, via food restriction, increase the ability of NIC and COC 
to increase locomotion and to produce conditioned place preference (CPP) (Bell et al., 
1997, Davis et al., 2007) as well as augmenting lateral hypothalamic (LH) ICSS reward 
effects.  When discussing and investigating the central reward circuit, the LH is a key 
brain focus (Cabeza De Vaca et al., 1998, Fulton et al., 2010).  
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 Convergent studies support the hypothesis that GHR administration increases the 
locomotion and hyperactivity effects of psychostimulants (Wellman et al., 2005) while 
both GHR administration alone and concomitant administration with psychostimulants 
increases accumbal DA overflow in the reward circuit (Jerlhag et al., 2006a).  Repeated 
daily administration of feeding-relevant doses of GHR (5 or 10 nMol) has been shown to 
result in a cross sensitization to COC when co-administered; also increasing locomotor 
responding to COC (Wellman et al., 2008a).  This appears to be made possible through 
GHR’s capacity to reorganize excitatory inputs in the reward circuit starting at the VTA, 
resulting in enhanced neural activation (Abizaid et al., 2006). 
The usual standard for investigating addiction is using a task in which a 
rewarding drug is self-administered via a jugular catheter.  Drug self-administration is 
studied in multiple phases (Carroll et al., 2004).  The first phase is acquisition, which 
involves being sensitized to the value of the reward and conditioned to respond for a 
reward.  In this phase, rats are shaped to lever press for the reward and over days show a 
progressive increase in drug intake.  Next is the maintenance phase, which is 
demonstrated by reward-seeking behavior and continued response for the reward, 
typically a plateaued response rate.  In this phase, the rat is seeking to maintain a fixed 
blood level of drug – as their response rates progressively increase when the drug 
infusion amount is cut from say 0.5 mg/kg/infusion to 0.25 mg/kg/inf to 0.125 
mg/kg/inf.  Lastly is the extinction phase where responding on a lever no longer leads to 
drug infusion.  During extinction, lever pressing gradually diminished to near zero.  
Once drug responding is extinguished, it is possible to examine reinstatement - where 
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there is restoration of the reward seeking behavior often due to exposure to the previous 
conditioned stimulus/the reward becoming available again.  Rats with higher serum 
GHR levels show higher incidence of reinstatement in COC self-administration after 
conditioned stimulus exposure compared to rats with lower GHR levels (Tessari et al., 
2007).  Self-administration of a reinforcer does not necessarily require exposure to drugs 
as GHR (also) increases sucrose, peanut-butter-flavored sucrose, and high fat pellet 
lever-responding in rodents (Perello et al., 2010, Finger et al., 2011, Skibicka et al., 
2011a; 2011b; Perello and Zigman, 2012). 
In 1954, James Olds reported that low level electrical stimulation of rat brain 
could be used as a reinforcer to guide behavior, described more below and in detail in 
Chapter III, Section 3.1.  This finding resulted in the ICSS task, which involves 
implanting an electrode into a brain area such as the medial forebrain bundle (MFB) of 
the LH, a collection of neurons that communicate between the NAc and the VTA, and 
allowing a rat to press a lever which in turn stimulates this area with pleasurable pulses 
of electrical current (Olds and Milner, 1954).  
The ICSS task is thought to tap into brain reinforcement mechanisms and 
procedures have been devised to examine how drugs of abuse alter ICSS patterns.  In 
one procedure, termed the rate-frequency procedure, the intensity of the electrical 
current is held constant while the frequency of the stimulation is systematically reduced 
downward each minute for 15 minutes.  The effect is that high rates of responding are 
noted at high frequency (e.g. 141 Hz) while rate of responding diminishes as frequency 
is reduced.  A notable advantage of this procedure is that it allows for the separation of 
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maximal rate of responding versus the shape of the curve.  A rewarding dose of COC (5 
mg/kg, for example) would not only increase the maximal rate of responding (the 100% 
value) but would also move the curve to the left such that the rat would continue to 
respond at frequencies that would be non-rewarding after vehicle (VEH). This is also 
called a shift in the 50% response rate. Were one only to look at 30-minute total 
responses, no such separation of action could be discerned.  
 The above studies take the approach of investigating the impact of GHR system 
activation on reward function; a second approach involves GHR system inactivation.   
Our laboratory is interested in investigating what occurs to drug and/or food reward 
upon activation and inactivation of the GHR system, particularly at the level of the 
reward circuit.  While activation of the GHR system can be accomplished using natural 
GHR (acylated or active GHR) and synthetic GHR (such as hexarelin) and were used in 
the experiments described above, several strategies have been developed to inactivate 
the GHR system (see Wellman et al., 2013 for a review).  In the present experiments, we 
focus on inactivating the GHR system through the use of the GHR-R antagonist, JMV-
2959 (Moulin et al., 2007, 2012; Salome et al., 2009a, 2009b). 
JMV-2959 is a derivative of the triazole structure (see Figure 5; Moulin et al., 
2012) that has low nanomolar affinity for GHR-Rs and is not a mixed agonist (Salome et 
al., 2009b, Wellman et al., 2012).  ICV infusion of JMV-2959 suppressed GHR induced 
food intake and blocked the increased food intake induced by periods of food 
deprivation (Bell et al., 1997, Wellman et al., 2012).  Central administration of JMV-
2959 suppresses GHR induced increases in body weight and fat mass, and blocks  
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the GHR induced decreases in energy use (Salome et al., 2009b).  Further, drugs of 
abuse such as NIC, COC and amphetamine cause increases in accumbal DA release and 
increases in locomotion, which can be blocked by pretreatment with JMV-2959 (Jerlhag 
et al., 2010, Jerlhag and Engel, 2011).  It has also been shown that rats treated with 
another GHR-R antagonist show less peanut butter or Ensure® intake, but show no 
change in standard chow consumption when given a choice (Egecioglu et al., 2010).  It 
is also important to note that mice lacking the GHR-R do not show a development of 
obesity when fed a high fat diet (Zigman et al., 2005).  Given these results, it can be 
speculated that the use of a GHR-R antagonist, like JMV-2959, would yield the same 
result and prove to be a practical approach to tackling overeating and obesity, 
independent of NIC use and cessation. 
Figure 5. Structure of JMV-2959. 
(Adapted from Moulin et al., 2012) 
GHR-R Antagonist 
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In this dissertation work, the focus was on examining the role of GHR-Rs on 
ICSS and IVSA of NIC or COC through GHR-R activation using acylated GHR and 
GHR-R inactivation using JMV-2959.  We also investigated weight gain following 
cessation of chronic NIC exposure via GHR-R antagonism and conclude with a focus on 
characterizing JMV-2959 by investigating the possibilities of it causing malaise when 
administered alone and/or in combination with NIC compared to known negative, 
malaise-inducing, control LiCl and positive control VEH.  
Our hope was to generate evidence to support our belief of GHR modulation’s 
role in drug reward in general and specifically to document that drugs such as JMV-2959 
may offer a possible dual-treatment approach for assisting in smoking cessation and 
withdrawal related weight gain.  The ability of JMV-2959 to prevent/mitigate any 
potential weight increases that are common in chronic smokers who attempt to quit, 
which is unfound in currently available options for assistance in quitting smoking, would 
be pivotal for this line of research. 
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CHAPTER II 
GENERAL METHODS 
 
2.1 Subjects 
The experiments utilized male Sprague-Dawley rats (Envigo).  All rats were 
allowed to adjust to the Psychology building vivarium for a minimum of 7 days on 
arrival before the start of any procedure or experiment.  All rats received continuous 
food and water and were housed on a 12:00 hour day/night cycle with the lights on at 
8:30 am and off at 8:30 pm for all experiments except Experiment 5, which utilized a 
reverse day/night light cycle.  All procedures were approved by Texas A&M 
University’s Institutional Animal Care and Use Committee. 
 
2.2 Housing 
 All rats were singly housed in standard polycarbonate cages.  The vivarium 
temperature remained between 68 and 72 °F (~21 +/- 1 °C), while the humidity was 
maintained at 60-70%. 
 
2.3 Drug Solutions 
 All drug solutions were kept sterile via filtration. 
2.3.1 Nicotine 
 Nicotine hydrogen tartrate salt ≥98% (HPLC) (Sigma item: SML1236) was 
calculated as the free base and dissolved into 0.9% saline to generate several doses:  
 24 
30 µg/kg/infusion, 1.4 mg/kg/day, and 0.4 mg/kg.  Each NIC solution was balanced to a 
~7.0 pH using sodium hydroxide.  
2.3.2 Cocaine 
Cocaine was dissolved into 0.9% saline to generate several doses: 0.5 mg/kg/.16 
ml 6 second infusion, 0.25 mg/kg/inf, 0.125 mg/kg/inf.  All doses were calculated as the 
salt.   
2.3.3 JMV-2959 
JMV-2959 was a kind gift from Jean-Alain Fehrentz of the Institut des 
Biomolécules Max Mousseron, Faculté de Pharmacie.  It was dissolved into 0.9% saline 
to generate a 3.0 mg/kg dose and a 6.0 mg/kg dose. An IP administration volume of 1.0 
ml/kg was utilized.  
2.3.4 Ghrelin 
A 5 nMol and a 10 nMol/rat acylated GHR (Phoenix Pharmaceuticals, 
Burlingame, CA, No. 031-31) concentration were dissolved into 0.9% saline and 
administered IP in a fixed volume of 0.5 ml. 
2.3.5 Sodium Pentobarbital  
Sodium pentobarbital was prepared by diluting a stock solution (Beuthanasia-D; 
Merck Animal Health, Madison, NJ) with 0.9% saline to a dose of 100 mg/ml at a 
volume of 1 mg/ml for IP administration and a volume of 7.5 mg/kg for IV 
administration via the jugular vein of those animals in Experiments 2-4, which also 
tested catheter line patency.  
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2.3.6 Lithium Chloride 
LiCl was calculated as the salt and a 32 mg/kg dose dissolved into a 0.9% saline 
solution was calculated.  An IP administration volume of 1.0 ml/kg was utilized.  
 
2.4 Consumables 
2.4.1 High Fat Diet  
A HIFAT diet was freshly made every third day of Experiment 5 and consisted 
of two parts ground chow (Teklad 8604 Rodent Diet; Madison, WI) and one part melted 
vegetable shortening (Crisco®; Orrville, OH) to create a 35.9% fat/16.3% protein mix 
with an energy content of 5.28 Kcal/g (see Wellman et al., 2005).  The diet was prepared 
by melting shortening and then mixed this into the ground chow.  The mixture was then 
allowed to cool to room temperature.  The HIFAT diet is richer in fat than is the CHOW 
by 23%, making it more attractive to the rats, contributing a rewarding property to the 
meal that will allow for greater/overconsumption versus typical CHOW consumption. 
2.4.2 Sodium Saccharin  
0.1% saccharin solutions were prepared fresh by dissolving saccharin chloride 
(Sigma Chemical) into tap water. 
 
2.5 Surgical Procedures 
2.5.1 ICSS Model 
For the ICSS experiments, a single stimulating electrode was implanted into the 
LH of each rat.  The pre-surgery injection regiment (IP) consisted of separate injections 
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of filtered: atropine sulfate (0.4 mg/kg), ketamine (60 mg/kg) and xylazine (20 mg/kg) 
for each rat. 
Upon verification of surgical plane of anesthesia, each rat was injected IM with 
sodium penicillin (200,000 units), prepared for surgery (body placed in a surgical sock; 
scalp shaved and cleaned) and its head mounted in the frame of a Kopf stereotaxic 
instrument.  Styptic gel (Kwik-Stop) was used to stop skull/scalp bleeding and lidocaine 
jelly (2%) was used as a local anesthetic.  The periosteum was pulled away with sterile 
clamps to allow for the necessary workspace.   
A bipolar, 0.125-mm wire diameter, stimulating electrode (Plastics One, 
Roanoke, VA; No. 303/3) was implanted into each brain. The incisor bar was set 
at −2.7 mm, and coordinates were 3.2 mm posterior to bregma, 1.7 mm lateral to 
the sagittal suture, and 8.3 mm ventral to the skull surface to place the electrode 
at the MFB at the level of the LH. (Wellman et al., 2008b) (Figure 6, Paxinos and 
Watson, 2004)  
 
Three skull screws were placed in skull quadrants outside the quadrant in which 
the electrode was placed.  The screws were then secured to the skull using cyanoacrylate 
glue and dental acrylic (Lang Dental; Wheeling, IL), allowing electrode anchoring onto 
the skull and providing protection from environmental damage.  Gentamicin sulfate 
ointment (0.1%) (E. Fougera; Melville, NY) was then applied to the incision, which was 
then closed using sterile cyanoacrylate (Vetbond: 3M; Maplewood, MN).  
 A subcutaneous (SC) injection of filtered buprenorphine (0.05 mg/kg: Dolorex) 
followed the surgery and a 7-day recovery was allowed.  Rats were weighed on a daily 
basis to monitor recovery for the remainder of the experiment.  
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2.5.2 IVSA Model 
For the IVSA experiments, indwelling jugular catheters were surgically 
implanted.  The pre-surgery injection regiment consisted of separate injections of 
filtered: atropine sulfate (0.4 mg/kg), ketamine (60 mg/kg) and xylazine (20 mg/kg), 
with each dose injected via IP into each ICSS rat. 
Chronic indwelling jugular catheters (Silastic tubing; 0.25-mm ID; Dow 
Corning; Midland, MI) were implanted into each rat.  Using sterile technique, an 
Figure 6. Lateral Hypothalamic (Electrode Target) Location on Atlas Plate. 
Coordinates for MFB at level of LH: 3.2 mm posterior to bregma, 1.7 mm 
lateral to the sagittal suture, and 8.3 mm ventral to the skull surface. The black 
dot on the right half of the panel shows the intended brain target.  
(Adapted from Paxinos and Watson, 2004) 
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incision was made at the neck above the right jugular vein, as well as an incision at the 
back just beneath the shoulder blades (Nation et al., 2003; 2004).  Lidocaine jelly (2%) 
was applied to these incisions served as a local anesthetic.  The catheter was placed 
within right jugular vein and anchored in place via suture to the periphery muscle of the 
vein.  The catheter was then routed from the neck area to the back between the scapulae 
subcutaneously with guidance using a stainless-steel tube (11-gauge).  The polyester 
mesh-based back-plate possessed a threaded cylindrical shaft with stainless steel tubing 
port to allow for connectivity to an infusion tether in the test box (Plastics One, 
Roanoke, VA; No. 313-000BM-10/SP).  Gentamicin sulfate ointment (0.1%) (E. 
Fougera; Melville, NY) was then applied to the incisions before being sealed with sterile 
cyanoacrylate. 
The back-plate was attached to a spring leash (Plastics One, Roanoke, VA; No. 
C313CS) in the test chamber that allowed the catheter to extend from the back-plate at 
one end to the other at a single channel plastic swivel positioned at the top of the test 
chamber (Instech, Plymouth Meeting, PA; SKU: 375/22PS).  The swivel interlocked 
with a connecting arm of the test chamber, allowing for free movement with the rat in 
the test chamber and for delivery of NIC or COC solution via tubing that continued on 
from the top of the swivel over to an infusion pump (Razel Scientific, Saint Albans, VA; 
Model R-E).  Depression of the left lever activated the pump via GraphicState software 
(Coulbourn Instruments, Whitehall, PA) while depression of the right lever was without 
effect. 
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Post-surgical discomfort was treated SC with 0.05 mg/kg buprenorphine and 
followed by a 7-day recovery.  Rats were weighed on a daily basis and given catheter 
flushing via infusions of sterile heparinized saline (1.25 U/ml) daily in the home cage to 
maintain catheter patency.  The catheters were also flushed before and after each daily 
test sessions with 0.20 mls of heparinized saline to prevent clotting and catheter 
blockage.  Upon completion of the study, catheter patency was tested using an infusion 
of sodium pentobarbital (7.5 mg/kg), resulting in a rapidly induced loss of righting.   
 
2.6 Histology Procedures 
At the completion of the ICSS experiments, sodium pentobarbital (100 mg/kg, 
IP) was used to euthanize each rat.  Following cessation of the heartbeat, a perfusion via 
the heart was performed using phosphate buffered saline (0.9%) and then formalin 
(10%).  For all other procedures, the rats were euthanized with CO2 to effect.  Following 
extraction, the brains of each ICSS rat were placed in 10% formalin/30% sucrose 
solution ≥72 hours.  Alternate 80µ frozen sections were then sliced, cover-slipped, 
electrode placements were verified using the Paxinos and Watson (2004) rat brain atlas. 
 
2.7 Apparatus 
2.7.1 ICSS Apparatus 
 The ICSS test chamber (Cambden Instruments) is a 28x22x22 cm stainless steel 
and Plexiglass box fitted with two levers mounted on opposite ends of one wall.  The 
right lever, when pressed, yielded no outcome, while the left lever depression delivered a 
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train of 300-ms monophasic rectangular pulses and lit a lamp above the lever.  A Grass 
S88 stimulator (Quincy, MA) and constant current stimulator (Digitimer, Model: DS3; 
Hertfordshire, England) were used to deliver a 0.3 second train of constant current pulses 
(at a selected frequency between 141 and 28 Hz) to the brain via a commutator and cable 
(Plastics One; Model No. SL2C and 305-305, respectively).  An oscilloscope (Jameco 
Electronics, Model: 645280; Belmont, CA) was used to monitor all stimulation activity. 
2.7.2 IVSA Apparatus 
 The IVSA test chamber (Cambden Instruments) is a 28x22x22 cm stainless steel 
and Plexiglass box fitted with two levers mounted on opposite ends of one wall.  The 
right lever, when pressed, yielded no outcome, while the left lever lit a lamp above the 
lever and delivered a single drug infusion (0.1 mL) via a single speed infusion pump 
(MedAssociates, St. Albans, VT; No. PHM-100) to the jugular via a single fluid channel 
flexible connector assembly (Plastics One; No. C313CS/SPC).  All administration 
parameters were monitored on an IBM compatible computer using the Graphic State 
software. 
2.7.3 Feeding Behavior/CTA Apparatus 
Rats in the feeding behavior study were individually housed and monitored on a 
DACB pad positioned under a wire grid floor while those in the CTA experiment 
remained in their standard individually housed home-cage environment (sawdust 
bedding). 
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 CHAPTER III 
EXPERIMENT 1: EFFECT OF JMV-2959 AND GHRELIN  
ON INTRACRANIAL SELF-STIMULATION 
 
3.1 Background 
Examining drug-induced locomotor sensitization can provide information about 
the activational effects of psychostimulants (Wellman et al., 2013).  However, such a 
task provides little information into the rewarding effects of psychostimulants as 
assessed in drug dose self-administration protocols.  While few studies have focused on 
the role of GHR in drug self-administration, rises in GHR serum levels have been shown 
to be associated with enhanced subsequent reinstatement for COC (Tessari et al., 2007).  
Yet there are other ways to look at drug-related reward other than looking at how drugs 
are self-administered.  
 ICSS is a measure of brain reinforcement – namely the maintaining of operant 
behavior in those areas relating to reward.  Lever responding, as mentioned above, 
results in a delivery of constant-current pulses via an electrode capable of being 
implanted within any brain region, with our work focusing on reinforcement circuits 
(Wise, 1996; Kenny et al., 2003; Carlezon and Chartoff, 2007; Wellman et al., 2008b), 
particularly the MFB between the VTA and NAc that course through the LH (Burkey 
and Nation, 1994). 
On the first day in the testing apparatus, the electrode-implanted rat’s threshold 
of minimal current needed to promote ICSS is estimated.  Once the current has been 
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determined, a shaping period is commenced in which the rat is trained to press the lever 
until it has developed a consistent rate of responding at a fixed frequency of 141 Hz, 
typically being capable of responding at a consistent rate above 20 responses per minute. 
The rat is run through trials to establish a baseline responding rate and then, using IP 
injections of psychostimulants, we can measure the behavioral influence of the drug on 
the reward circuit and ICSS.  Psychostimulants are understood to decrease the reward 
threshold and increase responding, whereas withdrawal states do the opposite (Markou 
and Koob, 1992).  
ICSS stimulation intensity can range from 70-300 µA (depending on the 
electrode placement).  In the rate frequency procedure, responding is recorded each 
minute and frequency of stimulation is decreased from 141 Hz to 28 Hz in 0.05 log 
steps.  Decreases in frequency (at a constant current stimulator) occurs every minute 
over a 15-minute period, creating 15 data points per pass (Carlezon and Chartoff, 2007; 
Zheng et al., 2013).  Four passes are conducted for each rat and the first pass is omitted 
due to potential confounds resulting from acclimation to the test chamber at the 
beginning of every test period.  The value of reward is related to a suitable wave 
frequency in this case, decreases in frequency result in reduced rates of responding and 
leads to active lever responding decreases to a point that the effort required to produce 
the desired reward is too high to continue seeking out the reward.  Thus, responding on 
the active lever typically decreases with lower stimulation frequencies.  
Here, GHR, GHR-R antagonists, and/or psychostimulants can be administered to 
measure concomitant effects of both electrical and pharmacological stimulation along 
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varying frequencies for those rats with an established baseline of response for a set 
current amplitude.  Antagonism of DA activity at the MFB and/or LH area allows us to 
see the effects of inhibition on the ICSS response behavior alone, as well as the effect on 
the augmented response of COC or NIC on ICSS.  Both are important for understanding 
the reward circuit and investigating potential cessation approaches for addiction.  
In fact, it has been shown that NIC lowers reward thresholds in an ICSS test 
(Kornetsky et al., 1979; Kornetsky and Esposito, 1979; Ivanova and Greenshaw, 1997; 
Markou, 2008).  This relationship of increased reward activation inversely reduces the 
threshold for reward seeking behavior in ICSS.  A reduction in reward threshold 
motivates the animal to respond, or to continue to respond for frequencies typically 
unattractive, as the effort input formerly was not worth the reward output.  It can also be 
shown that, alike withdrawal as a result of psychostimulant cessation, reduction of 
endogenous reward system activation leads to increased reward thresholds in the ICSS 
paradigm.  
 In a recent unpublished study by our laboratory, rats were trained and tested in 
the ICSS paradigm with NIC.  Put simply, psychostimulant drugs typically decrease 
thresholds and increase the rate of responding.  This NIC dose both increased the 100% 
response rate and induced a slight leftward shift of the curve (consistent with augmented 
reinforcement) (Figure 7).  In contrast, pretreatment with JMV-2959 reversed the 
leftward shift and generally suppressed ICSS responding.  A statistical measure of  
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the leftward shift is to compare the 50% figure metric between the curves to confirm that 
the drug is encouraging the animal to work harder and longer for rewards that previously  
held little to no value to them. 
In this study, we considered the impact of GHR-R inactivation (JMV-2959) and 
activation (5 and 10 nMol acylated ghrelin) on ICSS responding.  Our focus was to 
determine if GHR and/or JMV-2959 alone have the capacity to alter responding for 
Figure 7. Impact of JMV-2959 on NIC Augmented ICSS Responding. The 
results show rate frequency curves for rats treated with VEH, NIC (0.25 mg/kg) 
or a combined pretreatment of JMV-2959 and NIC. NIC both increased the 
100% response rate and induced a slight leftward shift of the curve (consistent 
with augmented reinforcement).  In contrast, pretreatment with JMV-2959 
reversed the leftward shift and generally suppressed ICSS responding. [N=5]  
(Unpublished data from the Wellman laboratory) 
ß Increase in 
100% Threshold 
 
ß Baseline 
Responding 
 
 
 
 
 
 
ß Suppression 
of Responding 
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ICSS, and if the changes previously seen in the NIC ICSS experiment in Figure 7 are 
only possible when JMV-2959 and NIC are concomitantly administered.  In an earlier 
preliminary study from our lab, it was noted that GHR reduced total ICSS responding 
over a 30-minute test period.  That result, however, was difficult to interpret and this 
experiment sought to clarify the effect of GHR using the rate-frequency testing 
procedure. 
 
3.2 Experimental Procedures 
3.2.1 Subjects 
This experiment utilized 15, ~250-275g, Sprague-Dawley male rats (Envigo)  
 
 
 
 
3.2.2 Behavioral Analysis 
 Table 1 outlines the timeline of the experiment. After recovery from surgery, we 
determined each rat’s preferred current for lever responding and shaped them to lever-
press for ICSS.  The shaping occurred at a fixed-ratio of 1 (FR1).  The minimum current 
Surgery Recovery Shaping Period  
Base- 
line 
Test 
Day 1 
Inter-
trials 
Test Day 2: 
JMV-2959 
Electrodes 
Implanted 
7 Days 
Recovery 
10 Rats 
Shaped 
on FR1 
2 Days VEH 2 Days  
3 mg/kg n=5 
or  
6 mg/kg n=5 
Surgery Recovery Shaping Period  
Base- 
line 
Test 
Day 1 
Inter-
trials 
Test Day 2: 
Ghrelin 
Inter-
trials 
Test Day 3: 
Ghrelin 
Electrodes 
Implanted 
7 Days 
Recovery 
5 Rats 
Shaped 
on FR1 
2 Days VEH 2 Days  10 nmol n=5 2 Days  5 nmol 
Table 1. Experiment 1: Effect of GHR and JMV-2959 on ICSS 
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sufficient to incite lever responding for the rat was determined (usually between 70-300 
µA) by increasing the intensity.  Once lever pressing was established (responding at 10% 
day to day variation), a series of 60-minute daily baseline trials commenced.  Each trial 
consisted of separate 15-minute passes in which the frequency of stimulation was 
lowered each minute from 141 Hz to 28 Hz (decreasing in 0.05 log units) and the current 
intensity remained constant.  During testing, each rat ran in multiple trials on separate 
days.  The first group (n=5) were injected with VEH on Test Day 1, given two days to 
reestablish baseline and injected on a final day with 3 mg/kg JMV-2959.  The second 
group (n=5) were injected with VEH on Test Day 1, given two days to reestablish 
baseline and injected with 6 mg/kg JMV-2959.  In a final group (n=5) each rat ran in 
multiple trials on separate days and were injected with VEH on Test Day 1, given two 
days to reestablish baseline and injected with 10 nmol GHR on Test Day 2, given two 
days to reestablish baseline and injected with 5 nmol GHR on Test day 3.  All injections 
were given via IP 5 minutes prior to commencing each trial.  The amount of active lever 
pressing was recorded for every 1-min interval for each rat throughout each 15 min pass 
for all 4 passes.  Following the study, all electrode placements were confirmed to be 
within the LH (see Chapter II, Section 2.5.1). 
3.2.3 Data Analysis 
The first pass of every daily trial was deemed an environmental habituation 
period and consequently discarded (Carlezon and Chartoff, 2007).  The total number of 
lever responses for each rat was taken and averaged by group condition (JMV-2959 dose 
and GHR dose or VEH) for the last 3 daily passes and a rate-frequency curve was 
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generated.  Separate ANOVAs were calculated in investigating the effect of treatment, 
frequency, and the interaction of treatment and frequency for JMV-2959 (3 and 6 mg/kg) 
groups (and their respective VEH control groups), while a repeated measures analysis 
was utilized for the GHR (5 and 10 nmol) groups on lever-responding for ICSS. The 
maximal response rate (100% response rate) and 50% response rate for each rat were 
computed for each group.  The initial ANOVAs of response rate for each drug condition 
were followed up by planned contrasts comparing group differences in 100% values and 
50% values.  A risk factor of p < 0.05 was considered statistically significant. 
 
3.3 Results  
3.3.1 JMV-2959 
To evaluate the impact of JMV-2959 dose on ICSS responding, the study first 
assessed the impact of 6 mg/kg JMV-2959 on ICSS responding versus a VEH control 
condition (n=5).  Because of concerns that this dose of JMV might represent the high 
end of the dose effect curve, we identified the need for an assessment of a lower dose (3 
mg/kg) of JMV-2959 on ICSS (n=5 rats).  Separate ANOVAs for both 3 and 6 mg/kg 
JMV-2959 showed a significant effect of frequency (F(1,14) = 28.329, p < 0.001 and 
F(1,14) = 17.91, p < 0.001, respectively).  Neither JMV-2959 dose exerted a significant 
effect of treatment or a significant interaction between treatment and frequency. A 100% 
response rate analysis revealed no significant difference in ICSS responding in 3 or 6 
mg/kg JMV-2959 pretreated rats compared to VEH.  Analysis of the 50% response rate 
also showed a no significant difference in responding following 3 or 6 mg/kg JMV-2959 
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administration compared to VEH.  Put simply, neither 3 mg/kg JMV-2959 (Figure 8A) 
nor 6 mg/kg JMV-2959 (Figure 8B) exerted any significant effect on ICSS responding 
across the rate-frequency curve.  
3.3.2 GHR 
Pretreatment with 5 or 10 nmol GHR failed to augment or diminish brain 
stimulation as the data shows identical response rates when compared to the VEH 
condition (see Figure 9).  A 100% response rate analysis revealed no difference in ICSS 
responding in 5 nor 10 nmol GHR pretreated rats compared to the VEH condition.  
Analysis of the 50% response rate revealed the same result in both 5 and 10 nmol GHR 
pretreated rats compared to VEH pretreated rats.  Put simply neither dose of GHR 
exerted any significant effect on ICSS responding across the rate-frequency curve.  
 
3.4 Interim Discussion 
The results of this experiment indicate that neither JMV-2959, at either 3 or 6 
mg/kg doses, nor GHR, at either 5 or 10 nmol doses, are capable of affecting reward 
seeking in the ICSS paradigm. Neither drug is capable of increasing responding at higher 
frequencies, nor encouraging responding at frequencies typically seen as unattractive. 
More specifically, neither JMV-2959 nor GHR pretreatment resulted in a change, much 
less a significant change in the 50% and 100% response rate of responding in rats. 
Our previous unpublished results showed that NIC, when given alone, is capable 
of increasing the 100% and 50% response rate. This result is often described as an 
increase in threshold and a left-ward shift in rate of responding, indicating an 
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augmentation in reward seeking. Alternatively, pretreatment with JMV-2959 prior to 
administration of NIC has been shown to reverse the left-ward shift in the rate-frequency 
curve of responding and to generally suppress ICSS responding when given in 
combination (Figure 7).  Those results lead us to this experiment to investigate the 
effects of JMV-2959 alone on ICSS responding.  
It was important to determine the capacity of JMV-2959 and GHR to alter ICSS 
responding alone because it not only allows us to confirm that ICSS is capable of 
functioning independent of GHR activation when placed in the LH, but that, specifically, 
JMV-2959 and GHR alter drug effects on ICSS via an action at GHR-R’s located 
 
 
Figure 8A. Impact of 3 mg/kg JMV-2959 on ICSS Responding. The results 
show rate frequency curves for rats treated with VEH and then 3 mg/kg JMV-
2959.  JMV-2959 (3 mg/kg) failed to increase the 100% response rate and failed 
to shift the curve (increase the 50% responding rate). [N=5]  
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Figure 8B. Impact of 6 mg/kg JMV-2959 on ICSS Responding. The results 
show rate frequency curves for rats treated with VEH and then 6 mg/kg JMV-
2959.  JMV-2959 (6 mg/kg) failed to increase the 100% response rate and failed to 
shift the curve (increase the 50% responding rate). [N=5]  
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Figure 9. Impact of GHR on ICSS Responding. The results show rate frequency 
curves for rats treated with VEH followed by 10 then 5 nmol GHR. Both doses of 
GHR failed to increase the 100% response rate and failed to shift the curve. [N=5]  
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upstream from the electrode placement, likely at the VTA as shown by Abizaid et al., 
2006.  
The capacity of JMV-2959 to only be capable of suppressing the reward-seeking 
when given in combination with NIC is a curious one when assessing our results.  
Psychostimulants also function at or just before the level of the VTA and, when JMV-
2959 is given prior to NIC, reward-seeking behavior for ICSS is mitigated. Perhaps it is 
the case that psychostimulants act on neurons possessing GHR receptors within the VTA 
to enhance the VTA-NAc reward circuit – thus JMV-2959 can antagonize NIC-enhanced 
responding (at the level of the VTA).  In the absence of NIC, reward is elicited by 
activation of the reward circuit starting at the MFB – a nexus that has no GHR receptors. 
Preliminary studies in our laboratory have shown that JMV-2959 is incapable of 
blocking the expression of NIC developed locomotor sensitization.  Our preliminary 
experiment only utilized acute exposure to NIC (only 1 day), however in a chronic tast, 
prior to pre-treatment with JMV-2959 just before NIC administration.  Perhaps JMV-
2959 would be incapable of preventing ICSS lever responding when given to rats 
pretreated with JMV-2959 following chronic exposure to NIC.  The next 2 experiments 
provide some insight into the effect of JMV-2959 on chronic exposure to NIC or COC, 
which may provide evidence for what to expect if we were to investigate JMV-2959 
pretreatment following chronic exposure to NIC or COC on IVSA. 
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CHAPTER IV 
EXPERIMENT 2: EFFECT OF JMV-2959 ON INTRAVENOUS  
SELF-ADMINISTRATION OF NICOTINE 
 
4.1 Background 
In the next two experiments, we examined the impact of the GHR-R antagonist 
JMV-2959 on self-administration of the psychostimulants NIC or COC.  As described 
previously, neither locomotor experiments, nor ICSS experiments, as they are a poor 
proxy for reinforcement, provide as much information into the rewarding effects of 
psychostimulants as do drug self-administration studies (Wise, 1996). 
 As explained previously, in the IVSA paradigm, the animal is implanted with an 
intravenous catheter within the jugular vein in the neck that allows the animal to be 
trained to lever-press for a IV delivery of a psychostimulant infusion, which in turn 
increases DA levels in reward areas (Di Chiara et al., 2004).  This allows for assessment 
of responding for the stimulant and the impact of an agonistic or antagonistic 
pretreatment on responding for the stimulant infusion (Carroll, 1985).  This 
reinforcement model allows for the rapid onset of NIC or COC ingestion comparable to 
that of humans who can ingest these drugs through the lungs. 
  For NIC or COC IVSA, the number of responses required to obtain the drug is 
typically set to a fixed ratio (FR) where the animal receives the NIC infusion upon X 
amount of successive responses, where X is value chosen by the experimenter.  On an 
FR1 schedule, the animal receives an infusion of NIC per one response of the active 
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lever; (FR2) requires two responses, etc. In the present study, the FR value was set to 2 
to allow for a moderate level of responding against which to judge the impact of 
pretreatment with 3 mg/kg JMV-2959.  What is important to our laboratory about this 
paradigm is that once the animal has acquired the appetitive behavior and is responding 
at a baseline rate, we can seek out pharmacological methods to enhance, alter, or ablate 
the drug-seeking behavior. 
In this experiment, we considered the impact of JMV-2959 on NIC IVSA 
responding in order to evaluate JMV-2959 as a potential treatment for maintenance 
phase drug addiction, a phase that is difficult to eliminate. 
 
4.2 Experimental Procedures 
4.2.1 Subjects 
This experiment utilized 6, ~300g, Sprague-Dawley male rats (Envigo) 
implanted with intravenous catheters (See Chapter II, Section 2.5.2). 
 
Surgery Recovery Shaping Period  Days 1-3 Day 4 Days 5-6 
Catheter 
Implanted 
7 Days 
Recovery 
Rats 
Shaped on 
FR1 
Baseline FR2 
NIC  
(30 μg/kg/inf) 
JMV-2959  
(3 mg/kg) 5 min 
prior to NIC 
trial 
Reestablishment FR2 
NIC  
(30 μg/kg/inf)  
Table 2. Experiment 2: Effect of JMV-2959 on IVSA of NIC 
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4.2.2 Behavioral Analysis 
 Table 2 outlines the timeline of the experiment. Once FR1 lever-pressing for NIC 
was acquired, the schedule was raised to FR2 and the rats were run through 7 days of 60-
minute baseline trials to establish a baseline response rate.  During each trial, the NIC 
dose of 30 µg/kg/infusion remained constant (Paterson et al., 2010).  Once baseline was 
established, each rat was pretreated with an IP injection of JMV-2959 (3 mg/kg) or a 
VEH injection 5-min before the next trial on the following day.  Following this test day, 
rats continued baseline trials (with VEH injections) for 2 days to reestablish baseline 
response rates and confirm that JMV-2959 has no lingering or permanent behavioral 
effects. 
4.2.3 Data Analysis 
For each trial, the total number of responses and infusions were analyzed for 
each rat.  An ANOVA was computed to determine differences between VEH and JMV-
2959 and recovery day conditions.  Mean group differences were examined using 
planned t-test contrasts and a p < 0.05 established statistical significance. 
 
4.3 Results 
 Figure 10 shows the number of active lever responses for NIC during VEH 
baseline, following pre-treatment of JMV-2959, and 2 consecutive recovery days. On 
VEH baseline days, rats averaged 30 lever presses for every 60-minute session for 30 
µg/kg/infusion of NIC.  On the JMV-2959 pretreatment day, active lever pressing for 
NIC was almost non-existent.  On the next 2 days, the rate of responding for NIC was 
decreased (in the absence of JMV-2959).  Repeated measure ANOVA revealed a 
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significant effect of days (F(3,12) = 4.5, p < 0.024).  On the 2 subsequent recovery days, 
responding for NIC increased over that noted after JMV-2959, but had not reached VEH 
baseline levels. 
 
 
 
 
 
 
4.4 Interim Discussion  
 The results for this experiment demonstrate the capacity of JMV-2959 to ablate 
continued NIC drug-seeking during maintenance phase addiction.  Prior to JMV-2959 
Figure 10. Impact of JMV-2959 on NIC IVSA Responding. Mean 
group total active lever presses on an FR-2 schedule of reinforcement for 
30 µg/kg/infusion NIC for rats treated on successive days with VEH, 3 
mg/kg JMV-2959, VEH and then VEH.  Repeated measure ANOVA 
revealed a significant effect of days (F(3,12) = 4.5, p < 0.024). [N=6] 
 
**	 *	
VEHICLE 
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pretreatment, the rats in this experiment were capable and willing to press an active lever 
for an infusion of NIC ~29 times during a 60-minute session.  The decrease in 
motivation to drug-seek can be seen by the consequential decrease in responding for NIC 
following JMV-2959 and can be confirmed to be an effect of the drug by the 
observations that followed on the Recovery Days.  
The purpose and hope of this study was that our investigations would lead us to 
find that JMV-2959 can mitigate or eliminate the continued drug-seeking in maintenance 
phase of addiction to NIC.  This investigation is important because, until now, all 
previous experiments that have sought to investigate the effects of JMV-2959 on reward-
seeking with psychostimulant modifications have done so with only acute administration 
of the psychostimulants (Jerlhag et al., 2009, 2010; Dickson et al., 2011; Jerlhag and 
Engel, 2011; Skibicka and Dickson, 2011; Skibicka et al., 2011a, 2011b).  The 
preparation for an IVSA experiment allows for the development of an addiction and the 
observation of an effect by a drug like JMV-2959 on the maintenance phase of addiction.  
After all, it is those individuals who are having trouble quitting and that are at risk of 
health issues and early mortality that we must aim to treat them.  In the IVSA paradigm, 
the animal learns to press a lever for the drug.  It gets to choose to take the drug, a 
measure not taken into account in any of the previous JMV-2959 literature.  These 
animals are allowed to develop a dependence and constant drug-seeking behavior in the 
context of the drug. 
   The results herein demonstrate that JMV-2959 has the ability to almost entirely 
ablate lever responding for NIC in the context of chronic exposure when compared to 
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VEH baseline lever responding for NIC (Figure 10).  These results support our notion 
that JMV-2959 may be a suitable candidate in suppressing active drug/reward-seeking 
behavior in chronic psychostimulant users, specifically smokers.   
While JMV-2959 has a half-life of 6 hours, the results for Recovery Day 1 and 2 
suggest that JMV-2959 had a slight residual effect that may be a result in a 
neuromechanistic change in these drug/reward-seeking circuits.  Further investigation 
into the temporal course of JMV-2959 is recommended, but the current results are the 
first to provide evidence JMV-2959 may be a suitable drug, in comparison to other 
currently available pharmacological options, in assisting chronic smokers in that are 
attempting to quit. 
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CHAPTER V 
EXPERIMENT 3: EFFECT OF JMV-2959 ON  
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE 
 
5.1 Background 
In compliment of the previous experiment, this experiment considered the GHR-
R antagonist JMV-2959’s impact on COC IVSA responding in order to evaluate JMV-
2959 as a potential treatment for maintenance phase COC addiction. 
 
5.2 Experimental Procedures 
5.2.1 Subjects 
This experiment utilized 9, ~300g, Sprague-Dawley male rats (Envigo) 
implanted with intravenous catheters (See Chapter II, Section 2.5.2). 
 
Surgery Recovery Shaping Period  Days 1-3 Day 4 
Catheter 
Implanted 
7 Days 
Recovery Rats Shaped on FR1 
Baseline FR2 COC  
(0.5 mg /kg/inf) 
JMV-2959 (3 mg/kg)  
5 min prior to COC trial 
Table 3. Experiment 3: Effect of JMV-2959 on IVSA of COC 
 
 
5.2.2 Behavioral Analysis 
 Table 3 outlines the timeline of the experiment. Once FR1 lever-pressing for 
COC was acquired, the schedule was raised to an FR2 and the rats were ru
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days of 120-minute VEH baseline trials to establish a baseline response rate.  During 
each trial the COC dose (0.5 mg/kg/0.16 ml 6 second infusion) remained constant.  Once 
baseline responding was established, each rat was pretreated with an IP injection of 
JMV-2959 (3 mg/kg) 5-min before the next trial the following day.  
5.2.3 Data Analysis 
For each trial, the total number of responses and infusions were analyzed for 
each rat.  Single sample t-tests were used to determine differences between VEH and 
JMV-2959 conditions.  Mean group differences were examined and a p < 0.05 
established statistical significance. 
 
5.3 Results 
Figure 11 shows the number of active lever responses for COC during VEH 
baseline, and then again following pre-treatment of JMV-2959.  On VEH baseline days, 
rats averaged approximately 60 lever presses for every 120-minute session for 0.5 
mg/kg/infusions of COC.  On the JMV-2959 pretreatment day, active lever pressing for 
COC was greatly reduced.  A planned within group t-test compared active lever pressing 
after SAL pre-treatment was significantly higher than lever pressing after 3 mg/kg JMV-
2959 (t(8) = 6.7, P< 0.001). 
 
5.4 Interim Discussion 
The results for this experiment compliment those of the previous experiment as 
JMV-2959 proved capable of mitigating chronic drug-seeking behavior for COC (Figure  
 50 
 
 
11).  The rationale for this experiment, as in the previous experiment, was that 
psychostimulants activate the dopaminergic reward circuit and therefore should produce 
comparable results if JMV-2959 is functioning on the same area at the level of the VTA 
to NAc. 
The potential for JMV-2959 to be capable of mitigating drug-seeking for both 
NIC and COC is an exciting one because it not only tells us that antagonism of GHR-Rs 
may be suitable for the treatment and elimination of the addiction of many 
psychostimulants, but that this drug may offer an avenue by which to treat COC 
Figure 11. Impact of JMV-2959 on COC IVSA Responding.  Mean 
group total active (black bar) and inactive (gray bar) lever presses on 0.5 
mg/kg/infusion cocaine FR2.  Vehicle vs. 3 mg/kg JMV-2959 responding 
t(8) = 6.7, P< 0.001. [N=9] 
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addiction.  There are currently no Food and Drug Administration approved treatments 
for COC addiction.  Indeed, treatment for COC addiction mostly focuses on supportive 
measures that aim to stabilize the symptoms of COC overdose (American Psychiatric 
Association, 2010).  As for the therapies currently available for treating NIC addiction, 
as discussed earlier, those available are not very successful and cause side effects that 
are likely to drive many to relapse.   
Again, these results support the findings in Experiment 2 and also support our 
notion that JMV-2959 may not only be a suitable candidate in suppressing active chronic 
drug-seeking behavior in smokers, but also suitable as a treatment for maintenance 
addiction for many psychostimulants.  A drug like JMV-2959 might not just be useful to 
help someone stop use, but also be capable of preventing future incidence and the 
potential of relapse likely instigated by a drug-taking context, visual, and odorant cues 
that often associated with heightened desire to use and relapse.  
It is important to continue investigating JMV-2959 in combination with other 
psychostimulants, and, as discussed before with ICSS, in models where psychostimulant 
exposure has occurred for chronic periods of time.  It is not currently known if JMV-
2959 is capable of inducing mechanistic changes with long-term treatment, such as 
already established sensitization, but given the results for these 2 experiments, it would 
be of interest to investigate the potential of JMV-2959 with long-term treatment.  
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CHAPTER VI 
EXPERIMENT 4: EFFECT OF GHR ON  
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE 
 
6.1 Background 
It is well understood that elevated GHR levels are associated with increases in 
reward seeking behavior.  It has been shown that GHR levels correspond to the 
reinstatement of COC IVSA in rats in that naturally increased GHR levels, or if 
increased via GHR injection, can augment the reinforcement of COC (Tessari et al., 
2007).  In this experiment, we considered the impact of systemically injected GHR on 
COC IVSA responding.  This allowed us to investigate the potential of increasing GHR 
levels on the possible consequent increases in lever responding for COC in rats in the 
maintenance phase of addiction.   
 
6.2 Experimental Procedures 
6.2.1 Subjects 
This experiment utilized 6, ~300g, Sprague-Dawley male rats (Envigo) 
implanted with intravenous catheters (See Chapter II, Section 2.5.2). 
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Surgery Recovery Shaping Day 1 Day 2 Day 3 Day 4 Day 5 
Catheter 
Implanted 
7 Days 
Recovery 
Rats 
Shaped 
on FR1 
Baseline Baseline VEH GHR (30 nmol) Washout 
COC (0.5 
mg/kg/inf) 
COC (0.5 
mg/kg/inf) 
COC (0.5 
mg/kg/inf) 
COC (0.5 
mg/kg/inf) 
COC (0.5 
mg/kg/inf) 
Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 
VEH GHR (30 nmol) Washout VEH 
GHR (30 
nmol) Washout Baseline 
Terminate 
COC (0.25 
mg/kg/inf) 
COC (0.25 
mg/kg/inf) 
COC (0.25 
mg/kg/inf) 
COC (0.125 
mg/kg/inf) 
COC (0.125 
mg/kg/inf) 
COC (0.125 
mg/kg/inf) 
COC (0.5 
mg/kg/inf) 
Table 4. Experiment 4: Effect of GHR on IVSA of COC  
 
 
6.2.2 Behavioral Analysis 
Table 4 outlines the timeline of the experiment. After recovery from surgery, 
each rat was trained to lever-press for COC (0.5 mg/kg/inf) on a FR1 schedule.  
Following acquisition of FR1 responding behavior, the schedule was raised to FR2 and 
the rats were run through 7 days of 120-minute baseline trials to establish a baseline 
response rate.  During each training and baseline trial, the COC dose of 0.5 mg/kg/inf 
remained constant.  Once baseline was established, each rat was pretreated with an IP 
injection of GHR (10 nmol), VEH, or nothing 5-minutes just before beginning each of 
the next 4 trials in which the COC dose was systematically halved over trial days to 
create 3 COC dose samples; 0.5, 0.25, and 0.125 mg/kg/inf.   
6.2.3 Data Analysis 
Two separate analyses were conducted for the active lever data of this 
experiment.  In the first, planned contrasts (t-tests) were used to determine the dose-
dependence of the COC self-administration procedure.  COC dosing started at 0.5 
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mg/kg/inf and over subsequent days was reduced by half (i.e. to 0.25 mg/kg/inf and then 
to 0.125 mg/kg/inf.  The expectation was that such dose changes would result in 
enhanced responding.  The last dose change was back to 0.5 mg/kg/inf and served to 
assess the reliability of the responding.  A second analysis consisted on planned 
contrasts comparing, at each COC dose, differences in responding after ghrelin 
pretreatment relative to vehicle pretreatment.  Between group differences of p < 0.05 
were deemed statistically significant. 
 
6.3 Results 
The rate of responding for COC as the dose was decreased resulted in the 
expected dose-dependent increases in responding (see Figure 12).  Planned contrasts 
indicated a significant increase in responding when COC dose was shifted from 0.5 
mg/kg/infusion to 0.25 mg/kg/infusion (t(4)=3.13, p < 0.01) and a significant decrease in 
responding when COC dose was increased from 0.125 mg/kg/infusion back to 0.5 
mg/kg/infusion (t(4)= 5.1, p < 0.009).  The shift from 0.25 mg/kg/infusion to 0.125 
mg/kg/infusion only slightly increased response rate (p=0.68).  Pre-treatment with GHR 
failed to affect IVSA responding for each dose of COC 0.5, 0.25, and 0.125 mg/kg COC, 
relative to the respective VEH baseline.  A final trial at the training dose of 0.5 mg/kg 
COC demonstrated the return to VEH baseline responding.  Collectively, these results 
indicate that GHR administration does not alter COC IVSA once maintenance phase 
behaviors/drug-seeking has been established.  
 
 55 
 
 
 
 
 
6.4 Interim Discussion 
The results for this experiment show that, while systematically decreasing the 
COC dose from 0.5 to 0.25 and then to 0.125 over days alone augments responding for 
the drug, pretreatment with GHR fails to alter the rate of responding for any of these 
doses (see Figure 12).   
The rationale for this experiment was based on previous studies that have shown 
that intra-VTA GHR administration results in changes in DA release in the NAc (Jerlhag 
Figure 12. Impact of GHR on COC on IVSA Responding.  GHR (30 nM) did 
not significantly alter self-administration rates for any dose of COC ranging from 
0.5 to 0.125 mg/kg/infusion. [N=6] 
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et al., 2006, Jerlhag et al., 2007, Quarta et al., 2009).  Consistent with these studies, our 
laboratory has examined changes in the behavioral actions of COC in rats given acute 
supplemental doses of GHR.  Systemic GHR administration facilitates acute COC hyper 
locomotion in rats (Wellman et al., 2005) and induces behavioral sensitization to COC 
(Wellman et al., 2008a) but, as seen in Experiment 1, GHR alone fails to increase 
frequency thresholds and response rates in the ICSS paradigm. Given these results, we 
speculated that GHR pretreatment for rats chronically exposed to COC and in the 
maintenance phase would show an increase in the rate of responding for COC during the 
120-minute session.  These results would provide a compliment to the findings of the 
previous two experiments.  
However, the results for this experiment show that rats that have already acquired 
COC IVSA do not vary their response rate when injected with GHR, suggesting that 
GHR may not augment chronic COC IVSA.  This may be due to the fact, again, that 
previous experiments utilizing JMV-2959 and psychostimulants have done so by 
exposing the animals to the psychostimulants only acutely.  Our testing here was an 
adequate test. It involved a chronic exposure design.  The rats in this experiment and the 
previous 2 had been exposed to the psychostimulant at least 10 days before JMV-2959 
or GHR was administered.  We utilized 3 doses of COC, all within the standard doses 
administered in the literature.  We also used a dose of GHR that is among the highest 
doses typically used. The results simply failed to show any evidence of a treatment 
effect.  
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Perhaps it is the case that JMV-2959 and GHR can alter acute psychostimulant 
effects, but once the exposure becomes chronic a divergence occurs in the capacity of 
both substances to have an effect on reward behavior.  For example, it has been show 
that GHR pretreatment alters acute locomotor COC sensitization, augmenting it, but it 
fails to alter ICSS or COC IVSA, both chronic tasks.  
It is the case that GHR-Rs have a degree of constitutive activity – meaning that in 
the absence of a GHR agonist, these receptors exhibit a near-maximal degree of activity 
(Holst et al., 2003; 2004).  An implication of such activity is that administration of an 
antagonist drug may reveal an action on reward whereas administration of an agonist 
might be without effect as was noted in the present study in which systemic GHR 
injection has no effect on COC IVSA.  
Future studies should investigate the effect of GHR on chronic NIC IVSA as well 
as self-administration paradigms utilizing sucrose pellets to determine if the effects of 
JMV-2959 and GHR are tied to psychostimulants, the paradigm, or reward in general.  It 
would also be of interest to determine if JMV-2959 pretreatment prior to GHR 
administration in the ICSS paradigm would have any effect given that GHR has 
previously been shown to cross-sensitize to COC when administered acutely.  
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CHAPTER VII 
EXPERIMENT 5: EFFECT OF JMV-2959 ON NICOTINE-WITHDRAWAL 
RELATED BODY WEIGHT GAIN 
 
7.1 Background 
It has been established that smoking is often used as a weight control strategy 
that allows users to increase caloric intake while remaining, on average, 10 pounds 
lighter than the average non-smoker (Dallongville et al., 1998) (Figure 13).  Cessation of 
chronic smoking results in an average weight gain of 3 pounds per 7 days of cessation in 
many users.  Which in turn can drive them back to smoking as 75% of women smokers 
nor 35% men smokers are not willing to gain more than 5 pounds if attributed to 
smoking cessation (Pomerleau and Kurth, 1996).  In this experiment, we used Wellman 
et al., 2005 experiment as a model.  
The Wellman et al., 2005 study was a 2x2 experiment in which animals were on 
one of 2 diets: HIFAT or CHOW and one of 2 drug treatments: SAL or NIC, forming 4 
groups: CHOW-SAL, CHOW-NIC, HIFAT-SAL, HIFAT-NIC.  Rats were initially 
acclimated to a reverse day-night cycle upon arrival and then to their assigned diet for 3 
days prior to the treatment period with SAL or NIC.  Rats are nocturnal creatures and 
therefore mimicking human drug taking would require treatment during their waking 
cycle, in the dark.  Smokers only smoke while they are awake and smoke at typically 
regular intervals across the day.  The experiment modeled this smoker’s behavior by  
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Figure 13. Wellman et al., 2005:Food Intake & Weight Gain After NIC. 
Panel A). Mean group caloric intake in kcals in male rats treated for 14 days 
with either 0.9% saline (VEH) or 1.4 mg/kg free base nicotine (NIC) 
maintained on either a chow (CHOW) or high-fat diet (HIFAT). During the 
10 days after cessation of NIC, all rats were injected daily with VEH. The 
vertical line above or below each symbol represents the SEM. Panel B). 
Mean group changes in body weight (g) in male rats treated for 14 days with 
either VEH or NIC maintained on either CHOW or HIFAT. During the 10 
days after NIC, all rats were injected daily with VEH. Means T S.E.M. An * 
denotes a significant (p < 0.05) difference.  Total daily caloric intake; Panel 
Treatment days: B=Baseline day; 1–14=drug treatment days; R1–
R10=Recovery days. (Adapted from Wellman et al., 2005) 
B 
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administering the treatment across the active, night, period.  Treatment occurred for 14 
days in which, food intake, water intake, and body weights were also recorded.  After 14 
days, Treatment was discontinued while all other measures remained and continued to be 
recorded. 
A key issue from this study was that NIC induced weight loss and weight control 
during the Treatment period, with the loss and control being greater for rats on a HIFAT 
diet versus a CHOW diet.  Cessation of NIC resulted in an initial spike in food intake in 
both HIFAT-NIC and CHOW-NIC groups, with those in the HIFAT-NIC group 
demonstrating a larger effect.  Cessation was also followed by comparable linear 
increases in weight gain in both HIFAT-NIC and CHOW-NIC groups.  The rate of 
weight increase over days for these groups was almost identical to those in the HIFAT-
SAL group, which displayed a consistent linear increase in weight gain over the entire 
experiment.  
The experiment here sought to evaluate the impact of JMV-2959 on NIC-
withdrawal related feeding behaviors, particularly the spike in food intake, and body 
weight change like those seen upon NIC cessation in the Wellman et al., 2005 study in 
order to determine the potential use of GHR-R antagonism tin preventing NIC cessation 
related increases in food intake and body weight gain or regain.  In this experiment, a 
shorter time period (7 days) was utilized. 
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7.2 Experimental Procedures 
7.2.1 Subjects 
This experiment utilized 20, ~300g, Sprague-Dawley male rats (Envigo) and 
followed the experimental procedure described in Section 2.1 of Chapter II with the 
reverse day/night light cycle. 
 
 
Days 1-3 Day 4 Days 5-7 Treatment Days 1-7 Recovery Days 1-5 
Housing & 
HIFAT Diet 
Adaptation 
HIFAT diet only 
23hr access Baseline 
VEH 
VEH 
JMV (3 mg/kg) 
NIC (1.4 mg/kg/day 
administered) 
VEH 
JMV (3 mg/kg) 
Table 5. Experiment 5: Effect of JMV-2959 on NIC-Withdrawal Weight Gain 
 
 
7.2.2 Behavioral Analysis 
 Table 5 outlines the timeline of the experiment. Upon habituation to individual 
housing on DACB pad with wired grid floored housing, the rats were placed on a 
HIFAT diet (n = 20) (diet described below) and allowed 23 h per day access to the diet 
for the entirety of the experiment.  The wired floors and DACB pads were used in order 
to measure food spillage (to the nearest 0.1 g) by the rats and consequently subtracted 
from the rat’s daily food intake measurement.  
Rats were acclimated to a spaced dark-phase IP injection design protocol of VEH 
(0.9% saline at 1 ml/kg volume injection) on baseline days 5,6, and 7, (VEH, 1 ml/kg) 
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administered at 0700, 1000, 1300, 1600, and 1900 h daily.  Days 1–7 were the drug 
Treatment period, in which rats were assigned (randomly) to an injection group of VEH 
(HIFAT-VEH group [n=10]) or NIC (1.4 mg/kg/day freebase; HIFAT-NIC group 
[n=10]).  The dose was determined by the weight of the rat prior to the first injection of 
the day (see Bellinger et al., 2003 for procedure).  We chose the dose of 1.40 mg/ kg 
NIC given that Wellman et al., 2005 states,  
One factor is that 70–75% of NIC given by the IP route used in the present study 
is removed by the liver during a single pass (Svensson, 1987) and thus did not 
reach the brain.  Humans smoking one to three packs of cigarettes per day take a 
total daily dose of approximately 0.3 – 0.5 mg/kg/day of NIC through their lungs 
(Benowitz and Jacob, 1984; Perez-Stable et al., 1998).  Therefore, the effective 
NIC dose in the present study [1.4 mg/kg in 5 injection/day] that reached the rat 
brain was about ̈0.42 mg/kg/day and is in the range of that used spontaneously by 
human smokers. (Wellman et al., 2005) 
 
After the Treatment period, all rat groups were split into two subgroups and 
given either VEH or JMV-2959 (3 mg/kg) injections (at the 0700, 100, and 1900-hour 
marks) during the subsequent 5-day recovery period to monitor food consumption during 
Treatment cessation.  This created 4 Post-Treatment groups: saline Treatment – saline 
Post-Treatment (VEH-VEH), saline Treatment – JMV-2959 Post-Treatment (VEH-
JMV), NIC Treatment – saline Post-Treatment (NIC-VEH), and NIC Treatment – JMV-
2959 Post-Treatment (NIC-JMV) [n=5 per group]. 
At 0600 h of each test day, each food cup and rat were weighed, to the nearest 
0.1g and gram respectively.  The DACB pad below the grid floor collected food spillage.   
It was weighed, recorded (nearest 0.1 g), and subtracted from the food intake for the day. 
Injections commenced with the dark cycle at 0700 hours.   
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7.2.3 Data Analysis 
7.2.3.1 Food Intake 
An ANOVA for the comparison of food intake during the Treatment period 
investigated a between-group factor (Treatment: VEH vs. NIC) and within group factor 
(Treatment Days 1-7) for food intake.  A second ANOVA was performed to determine 
the differences between Post-Treatment subgroups (VEH-VEH, VEH-JMV, NIC-VEH, 
NIC-JMV) during Post-Treatment Days 1-5.  A series of planned between-group t-tests 
were conducted to investigate food intake differences between Treatment groups (VEH 
vs. NIC) for each Treatment Day (1-7). A series of planned between-group t-tests also 
investigated differences between NIC-VEH and NIC-JMV Post-Treatment groups, as 
well as VEH-VEH and VEH-JMV Post-Treatment groups on Post-Treatment Days 1 and 
2, as Treatment cessation in Wellman et al., 2005 showed and initial spike in food intake 
following Treatment cessation. We were interested in mitigating this effect. Between 
group differences were examined using the Bonferroni measure and a p < 0.05 
established statistical significance.  
7.2.3.2 Body Weight 
An ANOVA was utilized for the comparison of change in body weight during the 
Post-Treatment period, specifically for the last day of Post-Treatment, day 5, JMV-2959 
between Post-Treatment groups (VEH-JMV and NIC-JMV) and VEH Post-Treatment 
groups (VEH-VEH and NIC-VEH). Between group differences were examined using the 
Bonferroni measure and a p < 0.05 established statistical significance.  
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Figure 14. Food Intake & Weight Change Properties of NIC on JMV-2959.  
Panel A). Mean group caloric intake in kcals in male rats treated for 7 days with 
either 0.9% saline (VEH) or 1.4 mg/kg free base nicotine (NIC) maintained on 
high-fat diet (HIFAT). During the 5 days after cessation of NIC, all rats were 
injected daily with VEH or JMV-2959 (3 mg/kg). Panel B). Mean group 
changes in body weight (g) in male rats Treated for 7 days with either VEH or 
NIC and Post-Treated with VEH or JMV-2959 relative to Treatment cessation.  
Panel descriptors: NIC 1–7 = Treatment days; JMV 1-5 = Post-Treatment days. 
[N=20]  
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7.3 Results 
7.3.1 Food Intake  
An ANOVA procedure revealed a significant difference between VEH and NIC 
Treatment groups on Treatment Days 1-7 (F(2,18) = 4.953, p = 0.039).  A second 
ANOVA revealed a significant difference between VEH-VEH, VEH-JMV, NIC-VEH, 
and NIC-JMV Post-Treatment groups during Post-Treatment Days 1-5 (F(4,16) = 5.874, 
p = 0.007).  
For all groups, with the exception of the NIC-JMV group, caloric intake 
increased over days (Figure 14: Panel A).  Upon NIC cessation and the beginning of the 
Post-Treatment period, rats in the VEH Post-Treatment groups (VEH-VEH and NIC-
VEH) showed a greater increase in caloric intake per day on Post-Treatment Days 1-5, 
while rats in the JMV-2959 Post-Treatment groups (VEH-JMV and NIC-JMV) 
displayed the opposite effect, with an immediate decrease in caloric intake on Day 1 of 
Post-Treatment that remained constant and persisted for the remainder of the study. 
Planned between-group t-tests revealed differences in Treatment groups’ (VEH 
vs. NIC) food intake during each Treatment Day (1-7).  However, this difference was 
only significant on Treatment Day 3 (t(8) = 2.268, p = 0.036).  
A planned between-group t-tests was utilized to assess the expected food intake 
spike, as seen by Post-Treatment Day 2 in Wellman et al., 2005, following Treatment 
cessation, for Post-Treatment groups (VEH-VEH, VEH-JMV, NIC-VEH, NIC-JMV) on 
Post-Treatment Days 1 and 2. A planned comparison revealed significant differences 
between NIC-VEH and NIC-JMV groups on Post-Treatment Days 1 and 2 (t(8) = 2.329, 
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p = 0.048 and t(8) = 2.478, p = 0.038, respectively).  Of interest, by Post-Treatment Day 
2, planned comparison also revealed significant differences between VEH-VEH and 
VEH-JMV groups (t(8) = 2.642, p = 0.029). 
7.3.2 Body Weight  
Figure 14 (Panel B) shows that after NIC cessation, rats in the JMV-2959 Post-
Treatment groups (VEH-JMV and NIC-JMV) displayed a reduced body weight increase 
relative to that of rats in the VEH Post-Treatment groups (VEH-VEH and NIC-VEH).  
These changes in body weight were confirmed in an ANOVA with a significant group 
difference on Day 5 of the Post-Treatment period (F(1,18) = 8.605). NIC Treatment 
cessation resulted in weight gain for the NIC-VEH group, however, this body weight 
remained lower than those rats in the VEH-VEH group.  The weight gain expressed by 
the NIC-VEH group was not noted in the NIC-JMV group. 
 
7.4 Interim Discussion 
The results for changes in food intake for this experiment were not at the 
magnitude of the NIC effect during the Treatment period as noted by Wellman et al., 
2005.  This experiment only focused on the effects of NIC on HIFAT intake (i.e. no 
CHOW group) and NIC exposure was halved to 7 days (as opposed to 14).  The results 
herein show that the NIC Treated rats show an initial suppression in food intake versus 
VEH Treated rats and that NIC and VEH groups have a slight positive linear trend over 
Treatment Days 1-7.  Once NIC is removed, however, and Post-Treatment begins, a 
divergence of food intake is noted.  Those subgroups Post-Treated with JMV-2959 
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(VEH-JMV, NIC-JMV) show a decrease in food intake that persists over the Post-
Treated VEH groups (VEH-VEH, NIC-VEH), which continue to progress in a linear 
fashion over the remainder of the experiment.  
In regards to changes in body weight during the Post-Treatment period, the body 
weight of those rats Post-Treated with VEH (VEH-VEH, NIC-VEH) displayed a linear 
increase in weight that is likely related to their linear increase in food intake after the 
cessation of NIC (Post-Treatment Days 1-5).  The rats Post-Treated with JMV-2959, 
however, showed a suppression of weight gain following NIC cessation.   
As stated previously, the focus of this dissertation work was to not only 
investigate the capacity of JMV-2959 to prevent continued drug seeking for NIC, but to 
also investigate the capacity of JMV-2959 to alter food intake in an effort to prevent the 
onset of obesity typically seen in individuals who quit smoking, individuals likely 
utilizing tobacco cigarettes as a weight control substance.   
Previous studies have shown that GHR administration is capable of stimulating 
food intake, increasing sucrose reward seeking (Figlewicz and Sipols, 2010, Dickson et 
al., 2011, Skibicka and Dickson, 2011, Skibicka et al., 2011a, Nakazato et al., 2001) and 
also results in an increased preference for HIFAT foods that leads to an increase in fat 
consumption (Shimbara et al., 2004) and leads to weight gain and adiposity (Wren et al., 
2001).  Conversely, GHR-R antagonism results in less peanut butter or Ensure® intake, 
but no change in CHOW consumption when given a choice (Egecioglu et al., 2010) and 
VTA damage results in a failure of GHR initiate increases in peanut butter consumption, 
however regular chow consumption remains unaffected (Egecioglu et al., 2010).  These 
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results lead to the conclusion that JMV-2959 may be suitable for the treatment of not 
only NIC cessation-associated weight gain, but also for the treatment of obesity alone.  
The data herein supports this notion, in that JMV-2959 alone is able to suppress 
free feeding and limit body weight gain, suppressing overconsumption of high fat food 
to normal CHOW feeding levels seen in Wellman et al., 2005 (~65 kcal/day in both 
NIC-JMV and VEH-JMV subgroups).  This decrease in consumption appears to curtail 
the continued weight gain in rats not exposed to NIC (VEH-JMV) as well as the weight 
gain, and the spike in food intake, associated with NIC cessation seen both in the 
Wellman et al., 2005’s HIFAT-NIC subgroup and in the NIC-VEH subgroup in this 
experiment.  
It is important to note that JMV-2959, however, is unlikely to work on the same 
mechanisms that suppress feeding through the use of NIC.  It is currently not understood 
how NIC alters feeding behavior and metabolism beyond its initial toxic effects, but the 
change in intake and body weight following cessation confirm that NIC exerts an 
inhibitory action on feeding and body weight, both in Wellman et al., 2005 and in the 
present study.  The HIFAT diet possesses a rewarding property, the fat, that makes it 
attractive and leads to its overconsumption.  JMV-2959 does not completely eliminate 
feeding, but instead suppresses feeding to homeostatic required levels, which implies 
that JMV-2959 is removing the rewarding value of the food and the rat is only 
consuming food to maintain energy homeostasis.  
This experiment is the first to investigate the effect of JMV-2959 on NIC-
cessation associated changes in food intake and weight gain as well as weight gain 
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typically seen following poor dieting leading to obesity.  The results lay the foundation 
to understanding JMV-2959’s potential as an obesity/overeating treatment strategy and 
potentially a dual-treatment method to fight NIC cessation relapse and NIC cessation 
related weight gain.    
  
 70 
CHAPTER VIII 
EXPERIMENT 6: EFFECT OF JMV-2959 ON  
CONDITIONED TASTE AVERSION INDUCED BY NICOTINE 
 
8.1 Background 
In previous experiments of this dissertation, JMV-2959 has suppressed reward-
seeking behavior in a psychostimulant enhanced ICSS task and the psychostimulant 
IVSA task.  This may occur because JMV-2959 blocks relevant reward circuits or 
because JMV-2959 induces malaise, which in turn nonspecifically suppresses behavior.  
In the CTA task, water intake is measured during a 30-minute period on 6 
successive days.  On a training day, each rat is offered a novel saccharin solution during 
the 30-minute period which is then followed by an injection of either VEH or a drug 
solution.  The saccharin solution, although possessing no caloric properties, is more 
appealing and the rats will typically consume more of it during this 30-minute period 
versus those bouts with just water.  When the treatment injection is a malaise causing 
agent, such as LiCl, the rat will exhibit an avoidance behavior towards the saccharin on 
subsequent presentations when it is presented again (Niijima and Yamamoto, 1994).  As 
a comparison, this is similar to eating a particularly appetizing dish and then coming 
down with a food-borne illness.  Consequently, the dish might be avoided for quite some 
time, if not indefinitely.  On days following the injection, both water and saccharin 
solution are made available during each 30-minute trial and the consumption volumes 
for both are recorded.  This allows for the calculation of the percent of saccharin of the 
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total volume consumed to determine the effects of the agent that was injected on the 
subsequent seeking and consummatory behavior of the saccharin.  No treatments are 
given on the subsequent days, often termed the Extinction Period.  Rats exposed to 
malaise inducing agents will typically display a high-preference for the water over the 
saccharin with an increasing trend favoring the saccharin over trials.  
In this CTA experiment, we aimed to assess the malaise properties of JMV-2959 
(with and without NIC) relative to LiCl (Kumar, Pratt, and Stolerman, 1983; McMahon 
et al., 1998; Garcia et al., 1968).  
 
8.2 Experimental Procedures 
8.2.1 Subjects 
This experiment utilized 25, ~300g, Sprague-Dawley male rats (Envigo) and 
followed the experimental procedure described in Section 2.1 of Chapter II. 
 
 
Days 1-6 (Baseline) Day 7 (Saccharin Exposure) Days 8-11 (Extinction) 
Open access to  
tap water from a drinking 
bottle 
VEH 
Open access to  
0.1% saccharin and  
tap water in separate bottles  
(bottle position alternated daily) 
NIC (.4 mg/kg) 
JMV (3 mg/kg) 
JMV (3 mg/kg) + NIC (.4 
mg/kg) 
LiCl (32 mg/kg) 
Table 6. Experiment 6: Effect of JMV-2959 on CTA induced by NIC 
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8.2.2 Behavioral Analysis 
Table 6 outlines the timeline of the experiment. During testing, standard housing 
water bottles were replaced with 100-ml graduated drinking bottles (Wahmann).  The 
rats were water deprived, daily, for 4 hours prior to each 30-min drinking session.  
Following a 30-min session, fluid intakes (nearest 1.0 ml) and body weight were 
recorded for each rat.  Fluid volumes were not corrected for spillage.  All sessions were 
conducted within the same time frame across days.  Food was continuously available 
throughout the studies.  
Days 1-6 were baseline days in which baseline fluid (water) drinking intakes 
were recorded.  Five groups (n=5 for each) of comparable daily average fluid intake 
were formed using the baseline values recorded during Baseline Days 1-6.  Rats were 
then randomly assigned to a treatment group: VEH, NIC (0.4 mg/kg), JMV-2959 (3 
mg/kg)(JMV), JMV-2959 pre-treatment (3 mg/kg) plus NIC (0.4 mg/kg), or LiCl (32 
mg/kg) group. 
On Day 7, the rats were offered a saccharin solution (0.1%) (Sigma Aldrich) in 
place of the standard water bottle.  Immediately after this session, each saccharin bottle 
was removed and the rats were injected with their assigned group drug schedule (listed 
above).  An Extinction Period followed for Days 8-11.  During each Extinction Day 
session, rats were allowed access to a water bottle and a saccharin bottle without further 
injections.  The positions of the bottles were alternated on a daily basis to control for 
position preference.  
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8.2.3 Data Analysis 
Three separate one-way ANOVAs were calculated (SPSS Version 23, St. Louis, 
MO).  The first was utilized to investigate differences across treatment groups for 
average baseline consumption of water for Baseline Days 1-6.  A second was utilized to 
investigate differences in saccharin consumption on the treatment day, prior to treatment 
injection (IP) (Drug Treatment: VEH, LiCl, NIC, JMV-2959, NIC + JMV-2959).  A 
Figure 15. Induction of CTA by LiCl in Contrast to the Effects of JMV-2959. 
The figure depicts average percent consumption of saccharin across groups on the 
day following exposure to only saccharin and treatment with either VEH, LiCl 
(32 mg/kg), NIC (0.4 mg/kg), JMV-2959 (3 mg/kg), or NIC and JMV-2959 
combined. [N=20] 
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final one-way ANOVA sought differences in the percentage of saccharin consumption 
versus total consumption when rats were given a choice of water or saccharin during the 
30-minute session on the first day of extinction.  A series of a priori t-tests were also 
computed to analyze planned comparisons between treatment groups.  A risk level of p < 
0.05 was set to establish statistical significance.  
 
8.3 Results 
A one-way ANOVA confirmed that all treatment groups consumed comparable 
levels of water during the baseline period, as well as saccharin on the Treatment Day 
(data not depicted).  A one-way ANOVA for baseline water consumption revealed no 
differences across all 5 groups, F(4,20) = 0.337, p = 0.849 (data not depicted).  A second 
one-way ANOVA for saccharin consumption prior to treatment exposure also found no 
difference across the 5 groups, F(4,20) = 0.488, p = 0.745.  A final one way ANOVA 
looked at the treatment effect on percent saccharin consumption when given the option 
of water or saccharin during the 30-minute session (Figure 15) and found the effect to be 
significant, F(4,20) = 3.106, p = 0.027. 
Planned between-group t-tests for Extinction Day 1 determined a significant 
difference in saccharin consumption between VEH and LiCl groups (t(8) = 3.955, p = 
0.004), as well as between JMV-2959 and LiCl groups (t(8) = 4.039, p = 0.004). 
Saccharin consumption for the JMV-2959 group was comparable that of the VEH group, 
showing no significant difference.  This confirms that JMV-2959 alone is unlikely to 
alter reward behavior as a side effect of inducing malaise.  While the VEH group almost 
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did (t(8) = 2.146, p = 0.0642), the JMV-2959 group (t(8) = 2.067, p = 0.0363) consumed 
significantly more saccharin than did the NIC treated rats.  However, VEH treated 
animals did not consume significantly more saccharin than animals co-administered NIC 
with JMV-2959 (t(8) = -1.550, p = 0.160).  
Two final t-tests determined that NIC treatment alone showed an effect of 
malaise comparable to that of LiCl (t(8) = 1.158, p = 0.280), which was seen also when 
comparing the NIC group to the group treated with a combination of JMV-2959 and NIC 
(t(8) = 1.576, p = 0.190).  These two tests support the notion not only is NIC capable of 
inducing malaise similar to LiCl, but that JMV-2959 is not capable of making NIC more 
aversive when co-administered.  This confirms that JMV-2959 does not induce malaise 
contingent on its combination with NIC, an effect that would alter the interpretation of 
previous research evaluating JMV-2959/psychostimulant combinations across 
paradigms. 
 
8.4 Interim Discussion  	In an unpublished study by our laboratory, JMV-2959 attenuated the rewarding 
action of NIC in the ICSS task, as well as NIC and COC-seeking in the IVSA tasks of 
Experiments 2 and 3.  This may occur because JMV-2959 blocks the rewarding substrate 
or because JMV-2959 produces malaise, which in turn suppresses behavior.  The present 
study confirms that the results of experiments utilizing JMV-2959, including all above, 
are not a result of JMV-2959 inducing malaise.  Figure 16 show the results in which 
LiCl was utilized as a malaise-inducing control, in causing avoidance of the saccharin in  
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Figure 16. Average Percent Saccharin Consumed Over Days. The average 
percentage of saccharin consumed increased at a linear rate for all groups over 
extinction trial days (ED). Animals treated with JMV-2959 (3mg/kg) showed 
consumption rates comparable to those in the positive vehicle control group. 
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future bouts, and VEH utilized as a regular control, for which rats prefer to consume 
saccharin whenever it is presented as an option.  NIC alone resulted in consumption 
levels falling between that of the LiCl and VEH controls, an understandable finding 
given that initial NIC exposure is understood to induce nausea, which in turn would 
result in malaise (Mishra et al., 2015).  An important finding of this study was that JMV-
2959 alone did not alter total fluid consumption on Extinction Day 1.  More importantly, 
however, was that JMV-2959 also did not alter the aversiveness of NIC when combined 
with NIC.  This is important because the studies here, and previous studies by other labs 
investigating GHR have seen suppression of behavior with JMV-2959, primarily when 
JMV-2959 injections were coupled with psychostimulant treatment.  This study strongly 
suggests that behavioral suppression in those situations in which JMV-2959 is coupled 
with a psychostimulant is not due to malaise.  
When looking at the progressive effects of the saccharin and injection exposure 
(Figure 16), we note that the consumption of the saccharin consumption remained low 
for those groups which experienced a degree of malaise (LiCl, NIC, NIC plus JMV-
2959), but shows some recovery at a positively increasing linear rate over days.  
Average percent saccharin consumption levels of VEH and JMV-2959 administered 
alone begin at 60% and climb to almost a 90% of all fluid consumption within 3 days of 
extinction versus malaise associated groups which remain under 50% for a majority of 
the study.  
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CHAPTER IX 
GENERAL DISCUSSION AND CONCLUSION 
 
 The results herein show that the GHR antagonist, JMV-2959, was capable of 
preventing the capacity of psychostimulants, NIC and COC, to be self-administered 
during maintenance phase addiction.  These two psychostimulants are thought to act via 
activation of DA cells within the VTA, in which GHR-R are located, while JMV-2959 is 
thought to block this activation of DA cells within the VTA (Abizaid et al., 2006, 
Skibicka et al., 2011b, Wellman et al., 2012).  In an unpublished pilot study, JMV-2959 
was also capable of blocking the excitatory effect of NIC on ICSS.  However, JMV-
2959 (3 or 6 mg/kg) is not capable of altering ICSS responding rates when administered 
independent of NIC. These results suggest that JMV-2959 is capable of altering 
enhancements, not only produced by psychostimulants administered acutely, but also 
capable of mitigating continued drug seeking in paradigms utilizing chronic NIC or 
COC administration, but not capable of affecting chronic ICSS activity when 
administered alone.  The latter is likely due to the ICSS electrodes placement 
downstream from GHR-R receptors of VTA neurons that JMV-2959 and GHR work on, 
allowing for ICSS reward-seeking to remain unaffected. 
 Moreover, GHR (30 nmol) pretreatment did not alter the reinforcing actions of 
COC in a self-administration task, regardless if COC was given at a large dose (0.5 
mg/kg/inf), a medium dose (0.25 mg/kg/inf), or a small dose (0.125 mg/kg/inf).  One 
explanation for these results is that COC acts on a GHR-dependent reward mechanism 
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such that augmenting GHR tone does not enhance reward whereas blockade of GHR 
tone does – this is consistent with the notion that GHRs have a degree of constitutive 
activity (Akamizu et al., 2004), meaning that, in most situations, GHR-Rs are always at a 
high level of tone and, thus, augmenting GHR may fail to increase response behavior. 
 JMV-2959 was also noted to suppress HIFAT intake and weight gain in VEH 
treated rats as well as under conditions following NIC treatment, which was also 
administered over days while the same HIFAT was made available.  Each outcome 
suggests a useful feature of the JMV-2959 molecule.  It can, not only, diminish appetite 
by itself, preventing overeating and slowing weight gain associated with poor, typically 
HIFAT, dieting, but it can also help to diminish the appetite spikes typically seen in 
smokers attempting to cease NIC use and as seen in our lab’s previous findings 
(Wellman et al., 2005), which would mitigate, or at least slow, the onset of weight gain 
seen following NIC-cessation when a HIFAT choice is available. 
 A key concern of the JMV-2959 literature is that this molecule may be capable of 
mitigating behaviors, such as those the IVSA and food experiments above, due to 
aversive properties that can diminish responding for food or drug-related reward.  This 
proposition is false for two reasons – the first is that JMV-2959 did not alter ICSS 
responding at doses that block NIC-enhanced ICSS when presented alone (unpublished 
data).  Secondly, a formal experiment herein compared the aversive properties of NIC, 
JMV-2959 and LiCl in a CTA task.  Whereas NIC treatment (0.4 mg/kg) produced 
evidence of CTA similar to that noted in rats treated with the prototypical aversive agent 
LiCl (32 mg/kg); JMV-2959 (3 mg/kg) alone did not.  One might ask if, perhaps, JMV-
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2959, when coupled with NIC or COC, augments the toxicity of the drug, as typically 
seen in NIC, during its initial use and as seen here in the CTA experiment.  However, 
concomitant administration of JMV-2959 and NIC resulted in comparable saccharin 
consumption on the day following treatment as those rats treated with NIC alone.  
Therefore, JMV-2959 is incapable of augmenting or synergizing the toxic effect of NIC, 
capable of inflicting a toxic effect in JMV-2959, nor capable of rescuing its toxic effects 
seen with NIC. 
 Many routes of NIC ingestion are available, however, smoking is the greatest 
form of concern when considering the health issues and morbidity associated with NIC 
use.  While many chronic users will attempt to quit smoking, via NRTs, cold turkey, or 
currently available pharmacological approaches, many will fall far short and their effort 
will not persist.  Tobacco companies are in the business of making money and do 
nothing more to prevent current and new users from falling into a financially and life-
threatening habit outside of slapping a small government-required warning label of, 
“SURGEON GENERAL’S WARNING: Smoking Causes Lung Cancer, Heart Disease, 
Emphysema, and May Complicate Pregnancy.” The choice and will is left in the hands 
of the smoker to acknowledge those warnings and give up the habit, a will most do not 
have. 
 Of course, a better strategy would be to prevent individuals from ever engaging 
in smoking and eventually becoming sensitized to NIC addiction.  While little is done, 
particularly pharmacologically, to prevent the onset of NIC addiction, it is important to 
note that prevention by any means (e.g. great parenting/parental control and good, legal, 
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business practice) may help prevent smokers, especially the young, from continuing use 
before becoming fully sensitized and transitioning into an addictive state in which they 
possess the compulsive urge to seek out and maintain the drug-induced state.  
Upon deciding to quit, users experience a rough period of withdrawal, with 
reoccurring symptoms so aversive that even a person who has experienced the 
occasional migraine might agree that productivity and quality of life might depreciate 
enough to turn back to smoking just to return to normalcy.  As discussed, for some, 
smoking is purely a desire by the user to obtain the reinforcing properties of the 
cigarette.  For others, however, it allows for the continuance of very poor feeding habits, 
typically heavy consumption of calories in the form of fat and alcohol (Dallongeville et 
al., 1998).  The benefit of the NIC use is that it also allows for a person to consume 
calorically dense fat and alcohol poor feeding habits without much consequence and for 
such users to weigh less than non-smokers (Klesges et al., 1989; Zoli and Picciotto, 
2012) - that is, until they try to quit smoking.  Withdrawal issues result in difficulty with 
treatment compliance, typically via NRTs, for those who see weight gain and are 
affected by stigmatizations and/or have weight-related health concerns (Pomerleau and 
Saules, 2007).  Sadly, there are only a few interventions tailored to assist in the smoking 
cessation while also mitigating the weight gain (Farley et al., 2012).  
This has led laboratories, like that of our own, to attempt to find a dual-treatment 
that tackles the urge to return to NIC from primary withdrawal symptoms and the weight 
gain from it.  Currently available methods for cessation do not assess the weight gain 
and those available pharmacological approaches that may have some promise in this area 
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fall short due to a lack of specificity that leads to symptoms that are just as horrendous as 
those that come with NIC withdrawal, if not worse.  It is therefore important to find a 
dual-treatment approach with a greater specificity with less to no symptoms generated 
that would outweigh the symptoms of NIC withdrawal typically leading the user back to 
smoking.  
The current literature strongly supports a key role for GHR and GHR-Rs within 
the VTA for the induction of reinforcement for multiple classes of reinforcers including  
food and perhaps other natural rewards, drugs of abuse and novelty (Jerlhag et al., 2009, 
2010; Perello et al., 2010; Dickson et al., 2011; Egecioglu et al., 2011; Jerlhag and 
Engel, 2011; Skibicka and Dickson, 2011; Hansson et al., 2012; Wellman et al., 2012).  
This suggests that there may be a therapeutic approach to addiction via these GHR-R 
receptors.  These GHR-Rs, along with cholinergic receptors, can be found on cholinergic 
neurons projecting from the laterodorsal tegmental area (LDTg) to the VTA.  Activation 
of the VTA then results in increased DA release within the NAc (Jerlhag et al., 2006b, 
Dickson et al., 2011).  This leads to the speculation that NIC may have the capacity to 
alter the activity of VTA neurons via the cholinergic receptors, while GHR antagonism 
can non-competitively block target the GHR-Rs to inactivate the same neurons.  This 
notion is supported by findings showing that GHR infusions into the LDTg enhance 
locomotion and induces NAc DA release (Jerlhag et al., 2007).  Conversely, acute GHR-
R antagonism blocks this effect, as well as the development of CPP by NIC, and the 
consequential DA increases within the NAc (Jerlhag and Engel, 2011).  While there is a 
mechanistic difference of action, all routes seem to lead back to the VTA and reward/DA  
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modulation circuit.  Figure 17 shows our theorized model of GHR influences on the 
reward circuit given the current findings in the literature. 
Our preliminary behavioral studies (Wellman et al., 2011, 2012) support the 
notion that JMV-2959, and drugs of similar structure, may provide an option for 
blocking psychostimulant-induced reinforcement.  In regards to our focus here, this 
would be of value when considering options for smoking cessation.  The literature 
regarding GHR-R antagonism for the prevention and mitigation of drug-seeking 
behavior is small and consists of only studies utilizing mice and rats and therefore 
requires, not only confirmation of these observations, but also demonstration that GHR-
R antagonists like JMV-2959 can aid in smoking abstinence.  
With regards to feeding behavior, injections of GHR into the VTA and the NAc, 
both acutely and chronically, can induce feeding (Naleid et al., 2005; King et al., 2011; 
Skibicka and Dickson, 2011; Skibicka et al., 2011a).  Palatable foods possess rewarding 
Figure 17. Theorized GHR Influence on Reward Circuit. 
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properties and the consumption of these foods is GHR-dependent, primarily for sweet 
and fatty foods (Egecioglu et al., 2010; Perello et al., 2010; Skibicka and Dickson, 2011; 
Skibicka et al., 2011b).  This suggests that GHR-R antagonism and GHR’s role here may 
not be limited to drug use, but may also be useful in the assistance to those who wish to 
control palatable food overconsumption.  This would set GHR-R antagonists up as a 
potential treatment method for those who are overweight and obese.  Experiment 5 
shows that this is indeed plausible, as JMV-2959 following NIC Treatment cessation, or 
VEH cessation slowed weight gain for the HIFAT diet rats.  This makes the reward 
circuit a prime candidate for investigation and supports our belief that GHR-R drug 
antagonists may have a dual utility for the treatment of NIC addiction: the first being 
antagonism of the rewarding action of NIC; the second being suppression of the weight 
gain often noted following smoking cessation (Wellman et al., 2013). 
 The experiments herein support the possible use of drugs like JMV-2959 in 
mitigating drug and food seeking during the maintenance phase of addiction while also 
mitigating the rewarding properties of food after NIC exposure, and potentially 
independent of NIC exposure, and preventing weight gain, as has been shown here.  The 
results for these experiments strengthen the notion that not only is GHR key to reward, 
but that GHR-R antagonism is a strong candidate for dual-treatment with possibly no 
side effects and greater specificity in eliminating NIC addiction while also mitigating the 
possible weight that is a major contributor to relapse. 
 Future studies should venture into investigating several areas.  First, as stated in 
the introductory chapter, is due to the general concern that women may be more 
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susceptible to smoking relapse due to standards created and pushed by mainstream 
media that women must be skinny in order to be considered attractive.  As noted, Vener 
and Krupka (1985) found that the obese are more likely to be stigmatized for being 
overweight/obese, while Pomerleau and Kurth (1996) found that women were unwilling 
to gain more than 5 pounds within a given month as a result of smoking cessation.  The 
current experiments only utilized male rats.  Due to the concern for women stated above 
and the ability of JMV-2959 to control body weight in male rats, investigations, 
particularly the feeding study, should be conducted utilizing only female rats.  Recent 
findings (unpublished 2016) by Carrie Ferrario’s laboratory have shown that the estrous 
cycle phase modulates cue-triggered motivation for food in obesity-prone but not in 
obesity-resistant rats.  This, of course, is not a contributing factor when investigating 
males.  Because of this, a drug like JMV-2959 may have the capacity to block this 
motivation and assist females that are obesity-prone.  It would, therefore, be of particular 
interest to investigate differences in HIFAT food intake and determining if female rats 
along different time points of the estrous cycle following and independent of NIC 
exposure.  
Another area of focus for future studies should seek to investigate the capacity of 
JMV-2959 to alter drug-seeking for substances with abuse potentials that are not 
classified as psychostimulants.  The experiments discussed herein only focused on two 
compounds, NIC and COC, but it may also be the case that GHR-R blockade may alter 
the reinforcing action and drug-seeking of ethanol, another highly concerning addictive 
substance with little to no pharmacological options for assistance in treatment.  Doyon et 
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al.’s (2013) investigations of the promotion of drinking via smoking reported that 
smokers have increased alcohol intake as well as a reciprocal interaction (Barrett et al., 
2006; Harrison et al., 2008; McKee et al., 2007; Weitzman and Chen, 2005).  In fact, 
83% of alcoholics also smoke (Burling and Ziff, 1988; Batel et al., 1995; DiFranza and 
Guerrera, 1990) and alcohol binging occurs more regularly in smokers versus non-
smokers (Harrison et al., 2008; Weitzman and Chen, 2005).  Given our findings, this 
would be the first logical step in investigating JMV-2959 on other drug systems.  
Previous studies by Uri Shalev’s laboratoy have determined that GHR has a limited role 
in heroin seeking and, therefore, should not be further investigated with JMV-2959 
(Maric et al., 2011), however, methamphetamine and THC may be of interest.   
 Investigations should also seek to utilize other pharmacological compounds and 
methods of inactivation of GHR and/or GHR receptors.  For instance, CF801, a novel 
peptide, reduces circulating acylated GHR levels by inhibiting ghrelin-O-acyltransferase, 
the only known enzyme capable of acylating (activating) GHR so that it is capable of 
binding to and activating neurons via GHR-Rs.  CF801 was recently shown to, acutely, 
decrease rebound feeding after an overnight fast, chronically decrease weight gain and 
adiposity without affecting caloric intake, and change in diet preference away from 
HIFAT (Wellman et al., 2015).  Given these early findings, it would be of interest to 
conduct, once again, an experiment similar to Wellman et al., 2005 and Experiment 5 
here with the use of CF801 instead of JMV-2959 to determine if CF801 has the capacity 
to reduce or eliminate the initial spike in food consumption and weight that occur upon 
NIC cessation.  Investigating this, as well as CF801’s capacity to alter ICSS and 
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psychostimulant IVSA would support the notion that GHR-R inactivation or simply the 
reduction of GHR availability via drugs like JMV-2959 and CF801, respectively, offer a 
possible dual-treatment solution for NIC addiction and weight gain associated with NIC-
cessation or general poor food diets. 
 Finally, Prader-Willi Syndrome is a genetic disorder that affects 1 in 10,000 to 
30,000 people worldwide (Genetics Home Reference, 2017). While in infancy, this 
disorder is characterized by hypertonia and poor weight gain, along with mental 
retardation and growth hormone insufficiency (Cassidy and Driscoll, 2009), however, 
beginning in early childhood and into adulthood, it is associated with elevated acylated 
GHR levels, consistent with hyperphagia, that lead to obesity in these individuals (Hagg 
et al., 2008; Purtell et al., 2011; Kuppens et al., 2015).  A mouse model of Prader-Willi 
syndrome has been developed by Jeffrey Zigman’s laboratory and, because of the 
elevated levels of GHR that lead to hyperphagia and obesity, as well as the results found 
in Experiment 5 here, it would be a suitable model for investigating what drugs like 
JMV-2959 may have to offer individuals with this disorder, as well as allow for a better 
understanding of the role of GHR in Prader-Willi Syndrome and in general. 
 Since 1998 our understanding of GHR and the literature has grown 
tremendously. GHR is no longer simply “The Hunger Hormone.” It has been implicated 
in neuroprotective roles when blood glucose levels drop, in mood, depression, stress and 
reward-seeking behavior for drug-reinforcers and natural reinforcers. There remains 
plenty to understand about GHR and its role in other symptoms. I look forward to 
continuing to contribute to this science for the years to come. 
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